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The goal of this research was to gain a better understanding of interplay between 
molecular biology, physiology, biochemistry, functionality with disease and interventions.  The 
primary findings of the first study were that there was a significant inverse correlation between 
homocysteine and brachial artery flow mediated dilation (BAFMD) and baseline brachial artery 
diameter.  Interestingly, there was a significant difference in BAFMD between methylene 
tetrahydrofolate reductase (MTHFR) genotype groups. Regression analysis indicated that the 
MTHFR genotype, homocysteine and age were significant predictors of BAFMD.   
 The second study revealed that vascular reactivity as measured by BAFMD was 
modifiable.  A meta-analysis of 22 intervention studies showed that exercise training produced 
significant changes in BAFMD. Fifteen of the twenty-two intervention groups had a statistically 
significant improvement in BAFMD.  Only one study had a negative effect size (ES). Larger 
changes in BAFMD were seen in “at risk/diseased” subjects compared to healthy subjects.  
Shorter duration studies (< to 8 weeks) had a larger mean ES than did longer duration studies. In 
regards to training type the aerobic group had the largest ES. The meta-analysis revealed that 
physical training produces a large change in BAFMD, a biomarker of vascular health.  
 Finally, study three revealed that middle-aged men and women instructed to 
consume a low-fat diet, reported, within 3 months, significant reductions in total fat, saturated 
fat, and cholesterol intake, which corresponded with a moderate, yet, significant change in LDL-
cholesterol. However, the diet intervention appeared to have only a modest effect on lipid 
balance as indicated by small reductions in the total cholesterol/HDL-cholesterol and LDL-
cholesterol/HDL-cholesterol ratios. Additionally, a clustering of lipid and vascular responses 
were seen indicating the array of responses to dietary interventions.  Gene-diet interaction 
evaluation did reveal that genetic polymorphisms, such as the deletion at the apolipoprotein B 
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signal peptide (24 amino acids) may be associated with varying responses to low-fat dietary 
interventions.  Interestingly, the data suggest that despite self-reported reductions in total fat, 
saturated fat, and cholesterol intake, markers of vascular “health” were not significantly changed. 
However, individuals’ brachial artery reactivity increased by 3 months in both groups, which 








Cardiovascular disease (CVD), a highly complex disease encompassing many related 
diseases of the cardiovascular system, is the leading cause of “morbidity and mortality” in 
America (Hoyert et al. 2005) CVD. Atherosclerosis is often the underlying condition which leads 
to most deaths. The process of atherosclerosis is continuous, beginning early in life and 
manifesting itself in large conduit arteries, as well as in the microcirculation. A variety of factors 
have been implicated in the pathogenesis of atherosclerosis. These include genetics, biochemical 
analytes, inflammation, vascular remodeling, nutritional and fitness status, male gender or post-
menopausal females, and numerous environmental and/or behavioral factors. This body of works 
aim is to evaluate several of these factors as they relate to atherosclerosis.   
The endothelial lining of the brachial artery plays an important role in the reactivity of 
the vessel and the ability of the artery to expand and contract in response to physiological 
stressors. The endothelium regulates many functions of the vessel including vascular tone, 
metabolism, and vascular cell proliferation.  It serves as a physical barrier for the vessel and 
controls permeability of substances into surrounding areas. Dysfunction of the endothelial lining 
has been linked to early stages of atherosclerotic disease (Ross, 1986). If endothelial dysfunction 
precedes the development of atherosclerosis, brachial artery flow mediated dilation (BAFMD) 
may be useful as a means of identifying patients with early atherosclerosis (Coretti, 1995). An 
advantage of the BAFMD is that it allows for non-invasive examination of the brachial artery as 
a measure of cardiovascular function. Assessment of BAFMD with ultrasonagraphy has been 
shown to be a stable and reproducible technique capable of differentiating between groups with 
normal and abnormal vascular function (Welsch, 2002; Frangi AF, 2003).  BAFMD correlates 
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with intima-medial thickness of the carotid arteries (Ravikumar, 2002) and to the extent and 
severity of coronary artery disease (Neunteufl, 1997).  Anderson (1995) and Takase (1998) both 
found that the brachial artery was a useful predictor of coronary reactivity.  The percent change 
in coronary artery diameter was shown to correlate to the percent change in brachial artery 
diameter (Anderson, 1995).  Likewise, Takase et al. (1998) showed that the coronary arteries 
stimulated with ATP were highly correlated to BAFMD. Additionally, an impaired BAFMD has 
been shown to independently predict long-term cardiovascular events in patients with peripheral 
artery disease (Gokce, 2003). 
In this dissertation, the non-invasive tool of BAFMD, a marker of vascular “health,” was 
utilized to anchor three separate projects which aimed to, in a stepwise fashion, evaluate different 
relationships between cardiovascular risk, vascular “health,” and the modifiability of the 
vasculature as measured by BAFMD. 
The first project consisted of a cross-sectional study from the baseline period of the 
REACH (Reduction in Early Atherosclerotic Changes) study in which biochemical analytes, 
vascular function, and related genetic variants were evaluated.  The purpose of this project was 
(1) to evaluate the associations between serum homocysteine, folate, vitamin B12, vitamin B6, 
and BAFMD; (2) to examine the possible influence of the methylenetetrahydrofolate reductase 
(MTHFR) genotype on homocysteine levels and BAFMD; and (3) to evaluate the effect of 
homocysteine, on the baseline diameter of the vessel versus BAFMD.  I hypothesized that 
plasma homocysteine would be inversely related to BAFMD and that individuals with the T/T 
genotype would have decreased BAFMD.  Additionally, I hypothesize that at least part of the 
effect of homocysteine on vasoreactivity is secondary to its effect on the baseline brachial artery 
diameter. 
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If BAFMD is a biomarker of vascular “health,” that correlates to both biochemical and 
genetics factors, then one might ask how it responds to interventions aimed at modifying 
vascular risk.  To gain additional insight into vascular function as it related to exercise and to 
assimilate published data and summarize whether vascular function was modifiable through 
physical training, the purpose of the second project was to conduct a meta-analysis on existing 
studies which examined the influence of exercise training intervention on BAFMD. 
Finally, the last project sought to determine the effect of a dietary intervention on 
BAFMD.  There are few dietary intervention studies utilizing BAFMD as a biomarker of 
vascular “health,” and these are limited to predominantly short term in duration..  These results 
consistently show that acute responses to high fat meals (Cortes et al. 2006; Tushuizen et al. 
2006; Ng et al. 2001) or “used” oil (Williams et al. 1999) produce decreases in BAFMD. The 
only long-term dietary intervention study, the Special Turku Coronary Risk Factor Intervention 
Project for Children (STRIP), found enhanced vascular reactivity in infant boys maintained on a 
low-saturated-fat diet from 7 months old until they were 11 years of age (Raitakari et al. 2005). 
However, results from calorie restricted diets over a short time period show conflicting findings 
(Brook et al. 2004; Raitakari et al. 2003; Jodoin et al. 1999). At the time of the final project, 
there were no studies in the literature that had reported the influence of a long-term dietary 
intervention on BAFMD and the role of genetic polymorphisms.. Thus, the final project sought 
to examine, in a population of middle-aged, asymptomatic men and women with normal 
cholesterol levels, whether reductions in dietary total fat, saturated fat, and cholesterol will 
significantly alter biomarkers of vascular health and whether any of these changes are related to 
genetic variability. I hypothesized 1) that long term adherence to a low fat diet would result in an 
improvement of cardiovascular risk factors including lipids, blood pressure, body mass index 
(BMI), body weight, body fat and BAFMD; 2) that this low fat diet would result in groups of 
 4
similarly responding individuals based on biochemical and genetic factors; and 3) that these 
groups identified would have differences in the magnitude of the effect of BAFMD. This final 
project aimed to provide further insight in the relationships that may exist between biochemistry, 
genetics, and vascular function in relation to a low-fat diet. 
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CHAPTER 2 
THE ASSOCIATION OF HOMOCYSTEINE AND RELATED FACTORS TO 
BRACHIAL ARTERY DIAMETER AND FLOW-MEDIATED DILATION* 
 
2.1 Introduction 
Plasma levels of homocysteine, an amino acid produced from the metabolism of 
methionine, are independently associated with increased risk for vascular disease (Clarke et al. 
1991; Boers et al. 1985; Kang et al. 1986; Stampfer et al. 1992; Arnesen et al. 1995) and have 
been shown to augment the effects of other traditional risk factors (Refsum et al. 1998).  Because 
of their intimate involvement in homocysteine metabolism, dietary intakes of folic acid, vitamin 
B12 and vitamin B6 are associated with homocysteine levels and therefore,  possibly the 
development of cardiovascular disease.  However, this relationship is complicated by the 
presence of genetic variation in a key enzyme involved in homocysteine metabolism, 5,10-
methylenetetrahydrofolate reductase (MTHFR). 
MTHFR is a critical enzyme in homocysteine metabolism that regenerates the active 
form of folate, 5-methyltetrahydrofolate, from 5,10-methyltetrahydrofolate.  Individuals with a 
genetic alteration in the MTHFR enzyme (nucleotide (nt) 677 C→T), which substitutes a valine 
for an alanine, have elevated plasma homocysteine concentrations which contribute to an 
increased risk for cardiovascular disease (Klerk et al. 2002).  Furthermore, individuals with 
coronary artery disease have an increased prevalence of the MTHFR variant compared to control 
subjects (Kang et al. 1991). 
Brachial artery flow-mediated dilation (BAFMD) has been proposed as a measurement of 
the degree and severity of cardiovascular disease and is used as a research tool in the study of 
cardiovascular disease (Coretti et al. 1995).  Assessment of BAFMD is related to structural  
 
*Reprinted with permission from Metabolism – Clinical and Experimental, 2007 May;56(5):641-8 
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changes of the carotid arteries (Ravikumar et al. 2002), coronary artery reactivity (Anderson et 
al. 1995; Takase et al. 1998), coronary stenosis (Kaku et al. 1998), and the extent and severity of 
coronary artery disease (Neunteufl et al. 1997).  Additionally, an impaired BAFMD has been 
shown to independently predict long-term cardiovascular events in patients with peripheral artery 
disease (Gokce et al. 2003).  Likewise, when evaluating patients with coronary artery disease, 
BAFMD has been shown to be an independent prognostic measurement (Bae et al. 2004; 
Neunteufl et al. 2000; Gokce et al. 2002; Brevetti et al. 2003; Perticone et al. 2001; Modena et al. 
2002; Fathi et al. 2004) and correlated to coronary events (Chan et al. 2003). 
Because of the prognostic ability of BAFMD, studies have examined the associations 
between BAFMD and cardiovascular disease risk factors, including homocysteine.   However, in 
this regard, the data are conflicting.  An association between BAFMD and fasting plasma 
homocysteine concentrations was found in subjects with hyperhomocysteinemia (Tawakol et al. 
1997) and between BAFMD and postprandial plasma homocysteine concentrations after 
methionine loading (Lambert et al. 1999).  Other studies with healthy individuals, however, 
showed no correlation between homocysteine levels and BAFMD (de Valk-de Roo et al. 1999; 
Hanratty et al. 2001).  The inconsistent findings in the literature concerning the relationship 
between homocysteine and BAFMD may in part be related to failure to account for a genetic 
variation in MTHFR.  
An additional factor may be a failure to consider the influence of homocysteine on the 
baseline diameter of the vessel.  Several traditional cardiovascular disease risk factors including 
body mass index, body surface area, weight, diabetes, hypertension, dyslipidema and an 
increased atherosclerosis risk score, influence the baseline brachial artery diameter (Holubkov et 
al. 2002). Given that the baseline diameter is inversely related to the BAFMD measure 
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(Celermajer et al. 1992), it is important to understand that risk factors may exert a direct or 
indirect effect on the vessel’s reactivity.   
Therefore, the purpose of this study was (1) to evaluate the associations between serum 
homocysteine, folate, vitamin B12, vitamin B6, and BAFMD, (2) to examine the possible 
influence of MTHFR genotype on homocysteine levels and BAFMD, and (3) to evaluate the 
effect of homocysteine, on the baseline diameter of the vessel versus BAFMD.  We hypothesized 
that plasma homocysteine would be inversely related to BAFMD and that individuals with the 
T/T genotype would have decreased BAFMD.  Additionally, we hypothesize that at least part of 




A total of 174 research subjects were available for study from the baseline period of the 
Reversal of Early Atherosclerotic Changes (REACH) by Diet study at the Pennington 
Biomedical Research Center.  The subjects consisted of 47 men and 127 postmenopausal 
women. These volunteers were recruited during a screening period based on an age range of 45 
to 66 years, an age and gender adjusted mean LDL-cholesterol between the 15th and 85th 
percentile, and HDL-cholesterol and triglyceride levels between the 5th and 95th percentile as 
defined by NHANES II data (Carroll et al. 1993).  Exclusions included a history of coronary 
artery disease (angina, myocardial infarction, or abnormal ECG), diabetes mellitus, systolic 
pressure ≥ 160 mm Hg, or diastolic pressure ≥ 95 mm Hg, use of medications for treatment of 
elevated lipids or hypertension, or a history of drug or alcohol abuse.  Following an explanation 
of the study and its benefits and risks, volunteers signed an informed consent approved by the 
Pennington Biomedical Research Center Institutional Review Board. 
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2.2.2 Brachial Artery Assessments 
Brachial artery assessments were obtained using high-resolution ultrasound (Toshiba 
Powervision SSA-380A with a 7.5-MHz linear array transducer) prior to, during, and following 5 
minutes of forearm occlusion. Individuals were instructed to fast and refrain from exercise for 12 
hours and alcohol for 48 hours prior to the measurements. Ultrasound images were obtained after 
15 minutes of supine rest. Images were obtained in longitudinal view, approximately 4 cm 
proximal to the olecranon process, in the anterior/medial plane. Image depth was initially set at 4 
cm, and gain settings adjusted to provide an optimal view of the anterior and posterior walls of 
the artery. Once settings were optimized they were kept constant. Imaging was performed on the 
non-dominant arm with the forearm extended and slightly supinated. Forearm occlusion 
consisted of inflation of a blood pressure cuff to 240 mm Hg for 5 minutes. Images were 
recorded on super VHS video tape for 30 seconds at baseline, and continuously from the final 30 
seconds of occlusion until 5 minutes post release. Digital still images captured during diastole, as 
defined by the onset of the QRS complex, were analyzed using specialized imaging software 
(Media Cybernetics, Image-Pro Plus). Arterial diameters (mm) were calculated as the mean 
distance between the anterior and posterior wall at the vessel-blood interface. Reproducibility of 
the technique, in our hands, has yielded average mean differences in vessel diameter change for 
days and testers of 1.91% and 1.40% with intra-class correlation coefficients of 0.92 and 0.94, 
respectively (Welsch et al. 2002). In that same study, the mean absolute difference in BAFMD 
between readers was 0.21± 0.014mm, with an intra-class correlation coefficient of 0.90 (Welsch 
et al. 2002). Baseline diameter was taken as the brachial diameter during the resting phase.  
BAFMD is defined as follows: Peak= (peak diameter after hyperemia minus the baseline 
diameter) x 100%/(baseline diameter). 
 
2.2.3 Laboratory Analyses 
Fasting blood draws were obtained after the imaging procedure or on a subsequent day.    
After aliquoting, samples were frozen at –80oC until analysis. Plasma homocysteine, vitamin B12, 
and folate analyses were performed on the Abbott IMx (Abbott Park, IL) utilizing Abbott IMx 
total homocysteine (tHcy), vitamin B12, and folate reagents, controls, and calibrators, 
respectively.  Plasma vitamin B6 levels were determined with ALPCO Diagnostics (Windham, 
NH) Vitamin B6 (pyridoxal-5’-phosphate) 3H-REA (radioenzymatic assay) according to standard 
protocol. Total cholesterol and triglycerides were determined as part of the lipid profile.  These 
were analyzed on the Beckman Synchron CX7 (Brea, CA) utilizing Beckman reagents and 
calibrators.  Sigma Diagnostics (St. Louis, MO) EZ HDL Cholesterol reagent was used on the 
Beckman Synchron CX7 for HDL-cholesterol analysis. LDL-cholesterol was calculated using 
the Friedewald equation. Genomic DNA was isolated from buffy coats by the method of John et 
al. (1991) and the prevalence of the nt 677 C T mutation was determined by polymerase chain 
reaction (PCR) and HinfI restriction enzyme digestion as described by Frosst et al (1995).  
2.2.4 Statistical Analysis 
Statistical analyses were performed using SPSS for Windows (version 11.0).  Data are 
presented as means and SD. To examine the associations between homocysteine, vitamin B12, 
vitamin B6, folate, and BAFMD, a partial correlation coefficient with height as a covariate was 
used. To examine the influence of the MTHFR genotype on BAFMD, a multivariate linear 
model was used. Finally, in order to determine the possible direct and/or indirect effect of 
homocysteine on BAFMD, multiple general linear models were compared with and without the 






2.3.1 Participant Characteristics 
 Participant characteristics, biochemical measurements, and brachial artery measurements 
for all subjects are shown in Table 2.1.  Participants consisted of 47 males and 127 
postmenopausal females within an age range of 45 to 66 years.  Additionally, the majority of all 
participants’ biochemical analytes were within normal ranges, including a participant 
homocysteine range of 3.5 – 15.8 µmol/L (normal range 5-15 µmol/L).  
2.3.2 Association of Homocysteine, Folate, Vitamin B12, and Vitamin B6 levels and BAFMD 
The data indicated strong inverse correlations between serum homocysteine and serum 
folate, vitamin B12, and vitamin B6 (r=-0.38, p=0.0001; r=-0.39, p=0.001; r=-0.17, p=0.025, 
respectively) (Table 2.2).  Additionally the data showed a significant inverse correlation between 
homocysteine and BAFMD (r=-0.18, p=0.020) (Figure 2.1).  In contrast, the data indicated no 
significant associations between serum folate, vitamin B12, or vitamin B6 and BAFMD. 
2.3.3 Influence of MTHFR Genotypes on Homocysteine Levels and BAFMD 
Of the 174 men and women who were analyzed for the MTHFR C677T genotype, 83 
were homozygous for the common allele, C/C (48%); 20 were homozygous for the variant allele 
T/T, (11%), and 71 were heterozygous, C/T (41%). No significant group differences for age, 
body mass index, lipids, blood pressure, heart rate, or baseline diameter were noted between 
genotypes. The average folate, vitamin B12, vitamin B6 and homocysteine concentrations were 
not significantly different between the three MTHFR groups.    In contrast, regression analysis 
incorporating MTHFR genotype and gender, and covarying for age, homocysteine, folate, and 
baseline diameter, revealed significant differences in BAFMD between MTHFR genotype 
groups (p=0.01) (post hoc comparison: )(T/T versus C/C p=0.042; C/C versus C/T p=0.13; T/T 
versus C/T p=0.003) (Figure 2.2). The correlation of homocysteine and folate by MTHFR 
genotype is shown in Figure 2.3. The correlation between homocysteine and folate was not 
affected by the MTHFR genotype. 
 
Table 2.1 Participant Characteristics, Biochemical Measurements, and Brachial Artery 
Measurements 
 
n Mean SD Range Minimum Maximum
Female 127 56 4.74 21 45 66
 Male 47 54* 6.08 19 46 65
Female 127 163 5.36 31 150 181
 Male 47 177* 6.44 31 158 189
Female 127 71.67 11.97 51.2 47.2 105.6
 Male 47 88.10* 12.77 54.8 61.4 116.2
Female 127 26.94 4.19 19.87 18.57 38.44
 Male 47 28.09+ 3.47 15.21 21.46 36.67
Female 127 123 13.61 71 67 168
 Male 47 121 13.15 57 85 152
Female 127 75 6.94 41 60 96
 Male 47 76 8.32 34 60 94
Female 127 66 8.92 48 45 93
Male 47 62* 9.49 40 43 83
Female 127 2.97 0.41 2.03 2.16 4.19
Male 47 3.81* 0.44 2.09 2.94 5.03
Female 127 5.25 3.89 14.23 -0.97 13.26
 Male 47 4.99 2.93 11.28 -0.32 10.96
Female 127 63 13.68 78 33 111
 Male 47 47* 7.49 36 34 70
Female 127 131 25.2 124 80 204
 Male 47 138+ 20.94 98 93 191
Female 127 125 56.5 370 33 403
 Male 47 139 84.1 566 25 591
Female 127 219 27.12 127 164 291
Male 47 213 27.1 126 159 285
Female 127 13.6 2.23 14.8 4.8 19.6
 Male 47 13.35 2 10.4 6.4 16.8
Female 127 529.99 287.63 1789 166 1955
Male 47 463.48+ 155.68 722 187 909
Female 127 83.89 97.97 515 3.9 519
Male 47 82.21 96.42 593 15.5 608.5
Female 127 7.2 1.85 9.8 3.5 13.3
Male 47 8.83* 1.88 10.5 5.3 15.8
 *p =0.05; +p =0.01 (females versus males)

















Vitamin B12 (pmol/L) 
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Table 2.2 























(umol/l)    
Baseline 
Diameter 
(mm)       
BAFMD 
(%)
r 0.31 0.26 -0.17 0.09 0.06
p 0.0001 0.001 0.025 0.23 0.45
r 0.28 -0.4 -0.06 -0.08
p 0.0001 0.0001 0.41 0.31
r -0.38 0.06 -0.09






































































Correlation between Brachial Artery Flow-Mediated Dilation and Homocysteine  
















































The Relationship between MTHFR genotype and BAFMD 
Data shows the mean ± standard error (SE) for each genotype 
(C/C genotype:  Mean=5.04, SE=0.37; C/T genotype:  Mean=5.9, SE=0..40; T/T genotype:  



















































Correlation of Homocysteine and Folate 
(y=-0.4543(x)+16.98; r=-0.394, p=0.001)  
 
 14
2.3.4 Relationship between Homocysteine, Baseline Diameter and BAFMD 
As previously stated, the association between homocysteine and BAFMD was weakly 
significant. However, analysis revealed that homocysteine was significantly associated with the 
baseline brachial artery diameter (r=0.19, p=0.013). Moreover, the data confirmed a significant 
inverse correlation between baseline diameter and BAFMD (r=-0.33, p=0.0001). 
Regression analysis using a multivariable general linear model indicated that the MTHFR 
genotype, homocysteine, and age were significant predictors of BAFMD (p = 0.0001, r2= 0.118) 
(Homocysteine: t = -1.97, p = 0.050; Age: t = -2.49, p = 0.014; and MTHFR genotype: p = 
0.008).  When the baseline brachial diameter was incorporated into the model, the effect of 
homocysteine on BAFMD was no longer significant. 
2.4 Discussion 
The present data confirms an association between homocysteine and BAFMD (Tawakol 
et al. 1997; Woo et al. 1997). Uniquely, the present study indicates reduced brachial artery 
reactivity in individuals with the MTHFR nt677 T/T genotype, despite similar blood values for 
folate and homocysteine. Finally, the present study suggests that the effect of homocysteine on 
vascular reactivity may in part be secondary to its influence on the vessel’s baseline diameter.  
Elevated homocysteine levels have been shown to increase cardiovascular disease risk 
proportionally (Refsum et al. 1998).  Even within the reference range of homocysteine levels of 
10 and 15 µmol/L there is a continuum of increasing cardiovascular disease (Robinson et al. 
1995).  Unlike the findings of some studies evaluating healthy subjects (de Valk-de Roo et al. 
1999; Hanratty et al. 2001; Pullin et al. 2002), our data show that homocysteine levels are 
associated with a decrease in reactivity of the vessel.  Although the relationship between 
homocysteine and reactivity was weak, these findings are intriguing given that the homocysteine 
values were all in the normal range. In fact, the homocysteine values in our participants ranged 
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from 3.5 – 15.8 µmol/L, with only one participant having a value greater than the normal range 
of 5-15 µmol/L.  Likewise, all folate levels were within or above the reference range, with only 
4% and 16% of the vitamin B12 and vitamin B6 levels, respectively, below the reference ranges.  
Even within these ranges there are strong inverse correlations between homocysteine and the 
nutritional analytes, folate, vitamin B12, and vitamin B6.  This information coupled with evidence 
that individuals with hyperhomocysteinemia have a marked reduction in vessel reactivity 
(Tawakol et al. 1997; Woo et al. 1997) and that there is a graded risk for homocysteine levels 
within the normal range (Refsum et al. 1998), further emphasizes the importance of minimizing 
homocysteine levels.  The possible mechanism that explains the apparent association between 
homocysteine and BAFMD is not entirely understood, but is thought to involve the influence of 
homocysteine on the bioavailability of nitric oxide, a mediator of vasoreactivity (Tawakol et al. 
1997) (Figure 2.4). 
Regarding the second objective of this study, the present data indicate reduced BAFMD 
in individuals with the MTHFR nt677 T/T genotype. The prevalence rate for the MTHFR nt677 
T/T genotype in this study was 11%, which is similar to the reports of Frosst et al. (1995) who 
found an incidence of 14% in a French Canadian population. Previous research has indicated a 
greater incidence of cardiovascular disease in patients with the MTHFR T/T genotype 
(Kluijtmans et al. 1996).  In fact, de Franchis et al. (1996) reported a relationship between 
MTHFR genotype and homocysteine levels and cardiovascular disease risk (de Franchis et al. 
1996). In contrast, de Bree et al (2003) reported no differences in homocysteine concentrations 
among MTHFR genotypes at high folate intake. The biological mechanism for the reduced 
vasoreactivity in individuals with the MTHFR T/T genotype in the present study cannot be 
explained by differences in plasma levels of homocysteine or folate as these were similar in all 






























Hypothetical Pathway by which an MTHFR Variant Increases Cardiovascular Risk 
 (L-Arg: L-Arginine, L-Cit: L-Citruline, qBH2: quinoid 7,8-dihydrobiopterin, BH4: 5,6,7,8-tetrahydrobiopterin) 
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derived nitric oxide (Joannides et al. 1995), our present findings may indicate an alteration in 
nitric oxide bioavailability in individuals with the MTHFR T/T genotype. 
Bioavailability of nitric oxide is affected by both nitric oxide production and degradation.  
Nitric oxide is synthesized by endothelial nitric oxide synthase which converts L-arginine to L-
citrulline. This reaction requires the presence of the essential cofactor tetrahydrobiopterin (BH4) 
(Cosentino and Katusic, 1995; Mayer and Werner, 1995).  Tetrahydrobiopterin ensures that 
endothelial nitric oxide synthase produces nitric oxide instead of superoxide (Verhaar et al. 1998; 
Doshi et al. 2001; Stroes et al. 2000). Tetrahydrobiopterin is produced from the inactive quinoid 
form (qBH2) in the presence of 5-methyltetrahydrofolate (Kaufman, 1991).  In addition, 5-
methyltetrahydrofolate may directly interact with the active site of endothelial nitric oxide 
synthase (Hyndman et al. 2001) resulting in nitric oxide production. Finally, evidence suggests 
that 5-methyltetrahydrofolate is involved in decreasing the degradation of nitric oxide, in part, 
because of a reduction of reactive oxygen species (Verhaar et al. 1998; Doshi et al. 2001; Stroes 
et al. 2000; Usui et al. 1999). Thus, decreased MTHFR activity may result in a decrease in nitric 
oxide availability due to a reduction in 5-methyltetrahydrofolate and/or tetrahydrobiopterin. 
Regarding the direct and/or indirect role of homocysteine on brachial artery reactivity, 
the present study indicates that homocysteine is correlated to both BAFMD and the baseline 
diameter of the brachial artery. In fact, multiple regression analysis strongly suggests that the 
effect of homocysteine on reactivity occurs predominantly through its influence on the baseline 
diameter with the diameter increasing with increasing levels of homocysteine. These findings 
contradict the findings of Wiltshire et al. (2002) who found that homocysteine was inversely 
related to the brachial artery resting diameter in diabetic children.  However, other studies have 
found cardiovascular risk factors, such as body mass index, glucose, blood pressure, and severity 
of coronary artery disease to be associated with an increase in the diameter of not only the 
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brachial artery, but also the common carotid artery and the coronary arteries (Holubkov et al. 
2002; Irace et al. 2001; Crouse et al. 1994; Irace et al. 1999; Glagov et al. 1987; Gnasso et al. 
1997).  It is presently not known how homocysteine influences the baseline diameter. 
Recognizing that vascular tone is predominantly affected by the autonomic nervous system, it is 
possible that homocysteine effects autonomic balance.  In fact, there is evidence that 
homocysteine levels are associated with autonomic neuropathy (Cohen et al. 2001). It is possible 
that early changes in autonomic balance may contribute to an increase in vascular resistance in 
smaller resistance vessels. As compensation to the changes in the resistance vessels, larger 
conduit vessels may initially increase diameter size in an attempt to normalize blood pressure. 
Other factors that may cause homocysteine to influence the vasculature include alterations in the 
coagulation system, increased platelet aggregation, increased H2O2 production causing 
endothelial damage, increased growth of smooth muscle cells, or a reduction in antioxidant 
levels (Refsum et al. 1998). Combined, these factors may contribute to structural and 
physiological alterations in different segments of the vasculature.  
Future studies are needed to evaluate whether the influence of individual cardiovascular 
risk factors on the reactivity of the vessel are direct (e.g. endothelial mechanisms) or indirect 
(e.g. autonomic balance).  In doing so, it will be possible to determine modulators of each effect 
separately, perhaps leading to new methods of reducing cardiovascular disease risk.   
The present findings were noted despite several limitations. Specifically, the ability to 
detect significant effects of the variables of interest may, in part, be limited due to the 
homogeneous nature of our study population.  It, certainly, is important for future studies to 
widen the study population (in terms of age, gender, ethnicity, physical fitness, and type and 
severity of disease). In addition, it should be noted that our study was conducted after folate 
fortification of grains and cereals (Rader et al. 2002), which may have accounted for the lack of 
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differences in homocysteine levels among the MTHFR genotypes.  Nevertheless, our data 
indicates promising new possibilities in the study of BAFMD and cardiovascular disease risk. It 
is well known that increasing folate levels will eventually compensate for the decreased enzyme 
in the MTHFR T/T genotype and result in normal homocysteine levels.  In fact, Christensen, et 
al (1997) found, that even though 5-methyl tetrahydrofolate levels were lower in the T/T 
MTHFR genotype, total folate was not significantly lower than in the C/C variant. Finally, our 
folate immunoassay measured total folate rather than individual forms of folate. Perturbations in 
the specific forms of folate could occur even though the total levels are normal. It is conceivable 
that the levels for the specific forms of folate differ between the MTHFR genotypes. This could 
then affect nitric oxide levels by the mechanism we propose in Figure 2.4.  
2.5 Conclusion 
In conclusion, the present data indicate that even within normal serum levels of vitamins, 
there are strong associations between homocysteine, and folate, vitamin B12, and vitamin B6 
levels.  There is also a relatively weak association between homocysteine and BAFMD.  The 
present data indicate reduced brachial artery reactivity in individuals with the MTHFR nt677 T/T 
genotype, despite similar blood values for folate and homocysteine. Finally, the present study 
suggests that the effect of homocysteine on vascular reactivity is in part a consequence of its 




EXERCISE TRAINING AND FLOW-MEDIATED DILATION: 
A META-ANALYSIS 
3.1 Introduction 
Cardiovascular disease (CVD) is the leading cause of death in the United States (Hoyert 
et al. 2005). Although CVD encompasses many related diseases of the cardiovascular system, the 
majority of deaths are secondary to the development of atherosclerosis. The process of 
atherosclerosis is continuous beginning early in life and non-discriminatory, manifesting in large 
conduit arteries, as well as in the microcirculation.  
A variety of factors including genetics, biochemical analytes, inflammation, vascular 
remodeling, nutritional and fitness status, male gender or post-menopausal females, and 
numerous environmental and/or behavioral factors have been implicated in the pathogenesis of 
atherosclerosis. Of particular concern in the development of the disease is that due to repeated 
challenges associated with many of the above factors, the endothelial lining weakens and breaks 
down, thereby leaving the vessel vulnerable to those factors known to contribute to the formation 
of lesions and plaques. For example, chronic hypertension may cause an elevation of the shear 
stress on the vessel wall, which eventually causes the vessel wall to deteriorate. Chronic 
hyperlipidemia may give rise to an excess oxidation of LDL near the vessel wall, which 
eventually may exhaust the buffering capacity of the endothelial lining and contribute to the 
break down of the vessel wall. Regardless of the specific mechanisms involved in the pathology 
of atherosclerosis it is slow in progression yet long in continuance (Booth et al. 2000). This is 
significant as an individual does not cross the clinical “threshold” of overt morbidity until years 
after the original cause of the disease has led to the breakdown of the vascular integrity and 
subsequent development of atherosclerotic lesions (Booth et al. 2000). For example, the 
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study (Zieske et al. 2002) 
indicates that atherosclerosis begins in childhood and the development of significant vascular 
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lesions may occur as early as young adulthood. Yet the manifestations of this disease usually do 
not occur until the 5th or 6th decade of life. Given the hypothesis that an initial injury to the 
vascular lining precedes the development of atherosclerosis, Booth et al. (2000) call for much 
greater emphasis on primary prevention strategies in an effort to prevent the enemy from 
organizing, in other words, to attack the roots of the problem rather then wait for the initial 
symptoms of the disease.  
 The hypothesis that a breakdown in the vascular endothelial lining precedes the 
atherogenesis has led to the development of biomarkers for vascular “endothelial” function. 
Brachial artery flow-mediated dilation (BAFMD) has emerged as a biomarker candidate for the 
measurement of the degree and severity of CVD (Laurent et al. 1990; Anderson et al. 1989; 
Celermajer et al.1992; Sorensen et al. 1995).  Due to the non-invasive nature and relative ease of 
use, BAFMD has become increasingly utilized as a research tool to monitor the efficacy of 
interventions designed to “turn-off” atherogenesis or improve vascular health. Two essential 
assumptions underlie the use of BAFMD as a biomarker for CVD: (1) BAFMD is an indirect 
measure of vascular endothelial health; and (2) the responses of the brachial artery serve as a 
window to the responses of the majority of the vasculature. The first assumption is supported by 
studies which have shown the vascular endothelium is essential for vasoreactivity of the vessel 
and dysfunction of the endothelial lining is linked to early stages of atherosclerotic disease (Ross 
1986).  The second assumption is supported by studies which demonstrate associations between 
BAFMD and that of the coronary arteries, along with the degree and severity of coronary artery 
disease (Corretti et al. 1995), and other markers of atherosclerosis, such as carotid intima-medial 
thickness (Anderson et al. 1995; Takase et al. 1998; Ravikumar et al. 2002; Kaku et al. 1998).  
Furthermore, BAFMD has been shown to independently predict cardiac events in patients with 
established cardiovascular disease (Gokce et al. 2002a; Gokce et al. 2003; Widlansky et al. 2003; 
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Patti et al. 2005).  These two underlying assumptions are the subject of continuing controversy, 
since not all researchers have been convinced of BAFMD’s usefulness as a biomarker for CVD, 
due to a significant number of potential confounding factors, such as the shear stimulus and the 
baseline brachial diameter.  Hence, a great deal of future work remains in order to fully 
understand the true nature and potential of BAFMD as a biomarker for CVD. 
Within the context of the stated problem the role of physical training on preserving 
cardiovascular health has gained enormous interest over the last 50 years. A great number of 
studies have been conducted to examine the influence of exercise training on cardiovascular 
health over the last 50 years. The evidence clearly indicates that a consistent exercise program of 
sufficient volume (duration, intensity and frequency) helps to protect cardiovascular health.  
Despite these definite and non-controversial findings, the precise mechanisms responsible 
for this protection are not fully understood. Certainly, the effects of exercise on the 
cardiovascular system are multi-mechanistic, involving several organ systems and controlling 
sites. However, given the potential vulnerability of the vascular endothelium in a certain milieu, 
one may speculate that the protective effects of physical training may in part be secondary to the 
preservation or improvement of vasoreactivity and/or endothelial function. Over the last 10 years 
several studies have been conducted to examine the influence of exercise training on BAFMD. 
The purpose of this study is to conduct a meta-analysis on existing studies which have examined 
the influence of exercise training intervention on BAFMD. 
3.2 Methods 
3.2.1 Search Strategy 
Data used in the meta-analysis were obtained by performing a literature search using 
PubMed, an electronic retrieval system developed by the National Center for Biotechnology 
Information (NCBI) for biomedical literature.  The search was performed for published papers 
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which reported exercise interventions and flow-mediated dilation of the brachial artery.  Search 
terms used were “flow-mediated dilation,” “vasodilation” and “exercise.” A total of 292 
abstracts, published between January 1999 and April 2006 were retrieved and subsequently 
examined for exercise training interventions and the dependent measure of BAFMD. 
3.2.2 Selection of Papers 
Criteria for the inclusion of studies in the meta-analysis were (1) a minimum exercise 
training intervention of at least one week; (2) reported values for BAFMD both pre- and post-
intervention; and (3) use of human subjects. Review articles, cross-sectional studies, pooled data 
from studies already included in the meta-analysis, studies in which no baseline BAFMD data 
were reported, and acute exercise intervention studies were excluded.  The final data set 
consisted of 21 exercise training interventions (Kobayashi et al. 2003; Rakobowchuk et al. 2005; 
Walsh et al. 2003a; Blumenthal et al. 2005; Gokce et al. 2002b; Watts et al. 2004a; Watts et al. 
2004b; Fuchsjager-Mayrl et al. 2002; Clarkson et al. 1999; Brendle et al. 2001; Kelly et al. 2004; 
Hamdy et al. 2003; Walsh et al. 2003b; Allen et al. 2003; Vona et al. 2004; Lavrencic et al. 2000; 
Moriguchi et al. 2005; Edwards et al. 2004; Maiorana et al. 2001; Guazzi et al. 2004; Belardinelli 
et al. 2005). However, because the study by Walsh et al. (2003a) conducted exercise training 
intervention with two independent hypercholesterolemia groups, one untreated group and one 
pharmacologically treated group, the final dataset consisted of 22 separate intervention groups. 
3.2.3 Data Entry 
In regards to data extracted from the selected papers, the following variables were entered 
in the master spread sheet in the form of means and standard deviations/errors for both the pre- 
and post-intervention: baseline diameter of the brachial artery, BAFMD, peak flow velocity and 
volume, number of participants, age, and fitness measures. Additional variables included gender; 
length of training; type, frequency, intensity and duration of training; and the health/disease 
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status of participants.  Study authors were contacted to obtain any data not reported in the 
original publications that were essential for conducting the meta-analysis.   
3.2.4 Analyses 
Meta-analytic procedures followed the steps outlined in the paper by Morris and DeShon 
(2002).  Because the intent of this meta-analysis was to test for differences across alternative 
treatments (i.e. intervention versus no intervention), and because the studies utilized different 
design methods, raw score metrics were used to compute the effect size estimates and their 
corresponding sampling variance (Morris and DeShon, 2002)  Effect sizes are scored such that 
positive values reflect either an improvement (increase) in BAFMD in the intervention group for 
the single group pretest-posttest design (identified by a single sample size value in Table 1), or a 
larger improvement in BAFMD in the intervention group compared to the control group in 
independent groups pretest-posttest design (identified by two sample size values in Table 1).  
Sample sizes, means, and standard deviations used in the meta-analysis were reported for 
all studies or obtained from the authors of the papers, except for the study by Guazzi, et al. 
(2004). Sample means and standard deviations for that study were extrapolated from Figure 4A 
provided in their paper (Guazzi et al. 2004).  Because none of the studies reported correlations 
between pretest and posttest measures for BAFMD, alternative methods/sources were used to 
obtain correlation estimates.  For the untrained or non-intervention (control) groups, the 3-month 
sample correlation reported in the REACH study (r = 0.57) was used (40).  For the trained or 
intervention groups, a correlation estimate of 0.479 was extrapolated from Figure 3 in the paper 
by Brendle et al. (2001). 
Because meta-analytic procedures rely on the normality assumption, histograms and 
normal quantile plots of the estimated effect sizes were checked for departures from normality.  
Publication bias was investigated using funnel plots and normal quantile plots.  In addition to 
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visual inspection of the funnel plots, a more objective approach based on regression analysis was 
used as well to check for publication bias (Egger et al. 1997a).  Another source of bias for raw 
score metrics is time effects.  For the single group pretest-posttest design, results from studies 
using a cross-over design were used as a basis for checking the significance of time effects.  For 
the independent groups pretest-posttest design, a separate meta-analysis was conducted on the 
non-intervention (control) groups to test for significant time effects.  Finally, tests for 
homogeneity of effect sizes were conducted using a Q statistic (Hedges and Okin, 1985). 
An overall test for homogeneity of effect sizes among all studies, as well as several 
subgroup analyses testing for potential sources of moderator effects, were performed.  For the 
subgroup analysis of disease status, only three studies (Rakobowchuk et al. 2005; Clarkson et al. 
1999; Allen et al. 2003) were classified as using healthy subjects.  Training length was classified 
according to the number of weeks of training (≤ 8 weeks training versus > 8 weeks of training).  
Type of training was classified as aerobic, resistance, or aerobic plus resistance for subgroup 
analysis.  Training intensity was classified as low (40 to 60% of performance maximum), 
moderate (60 to 80% of performance maximum), and high (> than 80% of  performance 
maximum). All analyses were conducted using SAS software, version 9.1.  
3.3 Results 
This meta-analysis examined data from 433 intervention subjects and 272 controls 
compiled from 21 exercise intervention trials in human subjects.  The various trials examined 
included both “healthy” subjects as well as transplant patients, individuals with chronic heart 
failure, obesity, hypercholesterolemia, coronary artery disease, polymetabolic syndrome, 
uncomplicated myocardial infarction, and diabetes in order to evaluate the efficacy of exercise 




Visual inspection of the histogram and normal quantile plot revealed that the estimated 
effect size distribution was symmetric in appearance and had no serious deviations from 
normality.  Additionally, visual inspection of the funnel and quantile plots revealed no evidence 
of publication bias in the dataset.  A more objective approach based on linear regression analysis 
was also performed using weighted effect size estimates since the majority of the studies used 
small sample sizes (Egger et al. 1997a).  There was no indication of a significant intercept for the 
BAFMD weighted regression analysis (p-value = 0.2122), suggesting that publication bias was 
not present in the dataset.   
Five of the nine single group pretest-posttest design studies (Walsh et al. 2003a; Watts et 
al. 2004a; Watts et al. 2004b; Walsh et al. 2003b; Maiorana et al. 2001) used cross-over designs 
in the training intervention.  None of these studies revealed a significant difference between the 
pretest BAFMD measures in the two groups, indicating that not only was the length of the 
washout period sufficient, but that there was no time effect present for the length of the training 
period.  Furthermore, in the relatively short lengths of the studies (8 to 24 weeks), a change in 
BAFMD would not be expected to occur in the absence of intervention.  Hence, bias due to time 
effects was not believed to be present in the single group pretest-posttest design studies.  The 
results of the separate meta-analysis of non-intervention (control) groups revealed an overall 
weighted mean effect size of -0.02 with a corresponding 95% confidence interval of -0.15 to 
0.11.  Due to the negligible magnitude of the effect size and the fact that its confidence interval 
contains zero, there appeared to be no evidence of a differential time effect in the independent 
groups’ pretest-posttest design studies.  To insure that this assumption held true for all studies 
included in the meta-analysis, a test for homogeneity of the non-intervention group’s effect sizes 
was conducted.  Results of this test revealed that the assumption of homogeneity did not hold 
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true for the non-intervention group (Q = 24.74, p= 0.0100).  However, none of the subgroup 
analyses performed yielded significant results for the non-intervention group and all of the 
confidence intervals computed about the subgroups’ effect sizes contained zero.  Hence, while 
no moderator variables were found to explain the heterogeneity present in the effect sizes for the 
non-intervention group, these mean effect sizes remained negligible.   
3.3.2 Brachial Artery Diameter 
Because of the relationship between the resting brachial artery diameter to BAFMD (43), 
the effect of exercise training intervention on the brachial artery diameter was also examined.  
The results revealed a non-significant mean effect size of 0.03 with a corresponding 95% 
confidence of -0.02 to 0.08.  Additionally, this non-significance was homogenous across all 
studies analyzed (Q = 26.62, p-value = 0.0865), thus indicating that all studies were behaving 
similarly in regard to the influence of exercise intervention on the brachial artery size. 
3.3.3 Effect Size 
The individual study’s effect size estimates along with its 95% confidence interval are 
found in Table 3.1, ordered smallest to largest effect size.  The overall effect size estimate (all 
studies combined) along with its 95% confidence interval on the effects of exercise intervention 
on BAFMD may be found in Table 3.2. While the overall effect size was large (0.91) and 
significant, the individual effect sizes used to compute this value did not come from a single 
population of effect sizes as evidenced by a significant overall test for homogeneity.  Hence, 
subgroup analyses were performed to test for significant moderator effects.  
3.3.4 Moderator Effects 
The results of the potential moderator effects analyses may be found in Table 3.2.  As can 
be seen in the table, training intensity and age category did not moderate exercise intervention 
effects on change in BAFMD.  However, the study design, disease status, training type, and 
Table 3.1 
Characteristics for each study in the meta-analysis on the effects of  






























1 Kobayashi et al. 2003 Adults with CHF 55±2 14/14 A/2 12 -0.02 (-0.76, 0.72)
2 Rakobowchuk et al. 
2005
Healthy adults 23±3.9 28 R/3 12 0.11 (-0.26, 0.48)
3 Walsh et al.2003b Adults with HC 52±2 11 RA/2 8 0.12 (-0.47, 0.71)
4 Blumenthal et al. 2005 Adults with stable 
IHD
63±10 48/42 A/2 16 0.27 (-0.14, 0.69)
5 Gokce et al. 2002 Adults with CAD 58±10 40/18 A/2 10 0.47 (-0.09, 1.04)
6 Watts et al. 2004b Obese children 8.9±1.6 14 A/2 8 0.52 (-0.04, 1.08)
7 Fuchsjager-Mayrl et al. 
2002
Adults with diabetes 42±10 18/8 A/2 16 0.6 (-0.25, 1.44)
8 Clarkson et al. 1999 Healthy adults 20±2 25/20 RA/3 10 0.71 (0.27, 1.15)
9 Brendle et al. 2001 Adults with PAD 69±1 19 A/2 24 0.88 (0.35, 1.42)
10 Watts et al. 2004a Obese children 14.3±1.5 19 RA/2 8 0.89 (0.36, 1.43)
11 Walsh et a. 2003b Adults with HC 
(drug)
52±2 11 RA/2 8 0.96 (0.23, 1.68)
12 Kelly et al. 2004 Overweight children 11±0.63 10/10 A/2 8 1.01 (0.08, 1.94)
13 Hamdy et al. 2003 Obese adults 49.3±1.9 24 A/2 24 1.02 (0.52, 1.52)
14 Walsh et al. 2003a Adults with CAD 55±2 10 RA/2 8 1.07 (0.28, 1.86)
15 Allen et al. 2003 Healthy adults 26±5.7 14/14 R/2 4 1.16 (0.36, 1.96)
16 Vona et al. 2004 Adults with MI 56±6 28/24 A/2 12 1.19 (0.60, 1.78)
17 Lavrencic et al. 2000 Adults with met syn 53±5 14/15 A/2 12 1.31 (0.51, 2.12)
18 Moriguchi et al. 2005 Adults with 
hypertension
42.8±10.1 15/10 A/1 12 1.35 (0.46, 2.23)
19 Edwards et al. 2004 Adults with CAD 58±8 9/9 A/2 12 1.63 (0.56, 2.70)
20 Maiorana et al. 2001 Adults with diabetes 52±2 16 RA/2 8 1.65 (0.88, 2.42)
21 Guazzi et al. 2004 Adults with CHF 52±5 16/15 A/2 8 2.45 (1.52, 3.38)
22 Belardinelli et al. 2005 Adults with CHF 55.9±15 30/29 A/3 8 2.5 (1.82, 3.18)
I = intervention; C = control; A = aerobic; RA = resistance and aerobic; R = resistance
ES = effect size; CI = confidence interval
PAD = peripheral artery disease; CAD = coronary artery disease; IHD = ischemic heart disease
CHF = chronic heart failure; met syn = metabolic syndrome
MI = myocardial infarction; HC = hypercholestemia
Intensity:  1=40-<60%; 2=40-60%; 3=>60%
ES 
estimate 
95% CI for 
ES
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length of training did influence the magnitude of change in BAFMD after exercise intervention.  
The independent groups study design had a significantly higher mean effect size than did the 
single group design (1.08 and 0.76, respectively; p = 0.0296).  Similarly, larger changes in 
BAFMD were seen in the unhealthy/diseased subject groups compared to the healthy subject 
groups (1.01 and 0.49, respectively; p = 0.0055).  Contrary to expectations, shorter duration 
studies of less than or equal to 8 weeks had a larger mean effect size (1.34) than did longer 
duration studies of 8 weeks or longer (1.34 and 0.66, respectively; p < 0.0001).  For the training  
type analysis, the aerobic group had the largest mean effect size, followed by the aerobic and 
resistance, with the lowest mean effect size found in the resistance group (1.02, 0.91, and 0.34, 
respectively; p = 0.0183). 
 
Table 3.2 
Moderator analysis for study variables predicting effect sizes for the meta-analysis on the effects 
of exercise intervention on BAFMD 
 
 Between classes effect,
QB (p-value)
Overall 79.30 (< 0.0001) 22 0.91 (0.76, 1.06)
Study type 4.73 (0.0256)
  Single group 10 0.76 (0.56, 0.96)
  Independent groups 12 1.08 (0.87, 1.30)
Disease status 7.70 (0.0055)
  Healthy 3 0.49 (0.16, 0.82)
  Unhealthy/Diseased 19 1.01 (0.85, 1.18)
Training Length 18.82 (<0.0001)
  ≤ 8 weeks 10 1.34 (1.10, 1.58)
  > 8 weeks 12 0.66 (0.48, 0.85)
Training type 8.00 (0.0183)
  Aerobic 14 1.02 (0.83, 1.21)
  Resistance 2 0.34 (-0.08, 0.77)
  Aerobic & resistance 6 0.91 (0.63, 1.19)
Training intensity 1.00 (0.6053)
  40 - < 60% 1 1.35 (0.39, 2.31)
  60 - 80% 18 0.88 (0.71, 1.05)
  > 80% 3 0.96 (0.65, 1.26)
Age category 0.38 (0.5363)
  Child 3 0.78 (0.35, 1.21)
  Adult 19 0.93 (0.77, 1.08)
k = number of studies; ES = effect size; CI = confidence interval; NA= not applicable












 Accumulating evidence that endothelial dysfunction is the initiating event for 
atherosclerosis has led to the emergence of BAFMD as a candidate for the measurement of the 
degree and severity of CVD (Laurent et al. 1990; Anderson and Mark, 1989; Celermajer et al. 
1992; Sorensen et al. 1995). Physical inactivity produces endothelial dysfunction, purportedly by 
diminishing pulsatile increases in blood flow, which gradually removes the stimulus for 
vasodilation, constriction, and vascular modifications. The purpose of this study was to conduct a 
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meta-analysis on published studies examining exercise training interventions and BAFMD in an 
effort to stimulate further appreciation for the possible manner through which exercise training 
may protect the vasculature.  The analysis reveals that exercise training indeed produces 
significant changes in the biomarker, BAFMD. 
3.4.1 Overall Effect Size 
This meta-analysis provides convincing evidence that a primary intervention, such as 
exercise training, significantly increases BAFMD and the effect seen is large.  If one agrees with 
the underlying assumption that BAFMD provides a non-invasive glimpse of the vascular 
systems’ ability to react to changes that occur within the cardiovascular structure, these findings 
suggest that regular exercise, specifically aerobic and to a lesser extent resistance, can improve 
one’s vascular health.  As can be seen in the Table 3.1, 15 of the 22 intervention groups had a 
statistically significant improvement in BAFMD (confidence intervals did not contain zero).  Of 
the seven intervention groups in which the change did not reach statistical significance, only one 
(Kobayashi et al. 2003) had a negative effect size.  Figure 3.1 graphically illustrates the effect 
sizes seen in all intervention groups. These findings verify that BAFMD is a sensitive biomarker 
which, in exercise training interventions, can detect changes in the vascular system. 
3.4.2 Moderator Effects 
•Subjects with Disease. While a large overall effect was observed for the combined 
studies, this effect was not homogeneous in nature, indicating that certain variables may be 
moderating the changes seen in BAFMD.  Of the moderator variables analyzed, the most 
influential factor appears to be a person’s health status. The analyses revealed that those 
individuals with disease (specifically diseases known to affect the cardiovascular system) 
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as “healthy.” Importantly, those classified as “healthy” also had significant, albeit smaller 
improvements in BAFMD. Some caution should be used in the interpretation of exercise training 
on BAFMD in the “healthy”, as only three exercise training studies were available 
(Rakobowchuk et al. 2005; Clarkson et al. 1999; Allen et al. 2003). Nonetheless, this meta-
analysis reveals two important points. First, the data indicate that vascular health is modifiable in 
“healthy” individuals, further illustrating the importance of including an exercise training 
component in primary disease prevention programs. Second, the data clearly indicate that 
individuals with evidence of reduced BAFMD stand to benefit greatly from exercise training, as 
it relates to vascular health. Given the evidence that the majority of individuals with disease also 
exhibited reduced BAFMD prior to training, these data lend support to the need to include 
exercise training as a major part of secondary disease prevention programs. 
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It is important to re-state that the current meta-analysis indicates that the magnitude of the 
BAFMD change, following exercise training, is in part a function of the initial or pre-training 
response. In fact, the data revealed a significant correlation between the initial BAFMD and the 
weighted effect size estimates (r = -0.46, p = 0.03).  This relationship implies that when the 
initial BAFMD measurement is low, the effect of exercise training on BAFMD is large and vice 
versa (i.e. when the initial BAFMD measurement is high, the effect of exercise training on 
BAFMD is small).  This finding obviously fits with most physiologic adaptations that the degree 
of change depends on the initial condition. The present observation confirms Green et al. (2004) 
who reported in both cross-sectional and longitudinal studies, that exercise training was more 
likely to increase endothelial function in subjects with compromised vasoreactivity than in 
normal subjects.  Likewise, studies have shown that diseased animals can both preserve normal 
endothelial function and normalize endothelial dysfunction through exercise training (Jasperse 
and Laughlin, 2006).
As previously stated physical inactivity may gradually remove the stimulus for 
vasodilation and vascular modifications. Data from the papers reviewed appear to show that in 
subjects with disease, as compared to age-matched controls, overall fitness is decreased.  
However, the reduced BAFMD certainly can be a function of a myriad of additional factors 
specifically related to the pathophysiology of the disease. Nonetheless, exercise training 
intervention does result in a large change in one’s vascular reactivity in a disease population. 
•Length of Training. A second important moderator in these analyses was the length of 
the training period.  Data revealed that shorter periods of exercise training (≤ 8 weeks) resulted 
in larger changes in BAFMD compared to longer periods of training (> 8 weeks).  These findings 
are interesting as they imply that changes in vasoreactivity in the vasculature occur rapidly after 
initiating training. In fact, in one of the participant studies by Allen et al. (2003) changes in 
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BAFMD occurred after only 4 days of initiating the exercise training intervention. These 
findings are consistent with the hypothesis advanced by Laughlin (1995) who speculates that 
following initial increases in vessel reactivity with exercise training, the reactivity returns to pre-
training levels after approximately three months, but at a greater diameter. He speculated that 
perhaps initial changes in shear stress as seen during exercise serves as a trigger for vascular 
adaptations, including changes in vasomotor tone, and/or vessel structural properties (Laughlin, 
1995). After the vascular adaptations are complete, vascular shear rates and consequently 
vascular reactivity are again normalized (Laughlin, 1995).  The fact that the current findings 
indicate that BAFMD is still modifiable beyond the initial eight weeks is interesting, and may 
indicate a continuation of the adaptive process due to training differences or may point at 
changes in additional vascular control systems.  
•Type of Exercise.  A third moderator of the changes in BAFMD with exercise training is 
the type of exercise performed.  Fourteen intervention studies used training which consisted 
primarily of aerobic exercise, six studies utilized a combination of aerobic and resistance 
training, while only two studies used resistance training alone. Importantly, changes in BAFMD 
were noted in most all studies regardless of modality. However, the greatest affect was seen in 
those studies utilizing exercise of aerobic nature or in combination with resistance training. The 
effect size for the resistance training alone subgroup did not reach statistical significance, 
implying that resistance training by itself may not be as effective in improving BAFMD.  
Obviously, this conclusion should be viewed with caution since only two intervention groups 
used resistance training alone and hence the statistical power to detect a significant effect may be 
too low.  Moreover, the effect sizes of the two resistance training studies were inconsistent, with 
the study by Allen et al. (2003) yielding a large, significant positive effect size (1.16) and the 
study by Rakobowchuk et al. (2005) yielding a small, insignificant positive effect size (0.11).  
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One noticeable difference between the two studies was the fact that Allen et al. (2003) used 
localized handgrip exercises, specifically targeting the muscle groups supplied by the brachial 
artery, while Rakobowchuk et al. (2005) employed a whole-body resistance training program 
which may have produced less of a direct effect on those same muscle groups. Irrespective of the 
above-mentioned issues, the findings of the meta-analysis support the American College of 
Sports Medicine (ACSM) guidelines for exercise training, which emphasize the need for a well-
rounded, whole-body exercise program. 
•Non-significant Factors.  Of interest is that age did not significantly impact the changes 
in BAFMD with exercise training. The studies under analysis ranged from approximately age 7 
to 78, with the majority of studies conducted in the 30 to 60 range. However, the fact that age did 
not influence the magnitude of the BAFMD change with exercise training is important as it 
implies that vascular function is modifiable in young and old.  
An inherent limitation to the current analyses is the inability to adequately and 
consistently quantify the volume (intensity, duration, frequency, and progression) of training 
performed. This clearly is an important issue that needs to be resolved in order to have a greater 
understanding of the dose-response relationship. The current analyses did not reveal exercise 
volume as a major moderator to the BAFMD response. The only affect noted was a small 
difference between the three categories of training intensity. The data revealed that the effect 
sizes for the two higher intensity categories, 60 – 80% and > 80%, appeared to be more similar 
than the effect size for the lower intensity category, 40 - < 60% (0.88, 0.96, and 1.35, 
respectively).  It is interesting to recognize that the greatest effect size was actually seen in the 
lowest intensity category. We remain cautious in the interpretation as this category was defined 
by only one study, involving adults with hypertension. However, it is clear that the typical 
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prescription of exercise as recommended by the ACSM, yields a change in BAFMD. Future 
studies, however, are indeed needed to further explore the dose-response relationship.   
3.4.3 Mechanisms for Change 
It is interesting to speculate on the mechanisms surrounding the changes induced by 
exercise training. One possibility is that the action of the muscles within the vascular bed causes 
an intermittent change in the shear stress on the vascular wall. It may be that the muscle action 
contributes to a modulation in the shear stress which stimulates the endothelial lining to adapt, 
contributing to an increase in vasoreactivity.  Indeed, evidence from animal studies indicates that 
repeated bouts of high shear stress stimulate the vascular and surrounding tissues early in 
exercise training. Animal studies have shown that it is possible that there is an increase in 
endothelial nitric oxide synthase (eNOS) protein expression, nitric oxide (NO) bioavailability 
may be elevated, other endothelium-mediated dilators may be altered, or vascular smooth muscle 
may gain an increased sensitivity to dilators (Laughlin et al. 2003). It has been shown that 
mRNA and corresponding proteins such as eNOS rise as early as 2-4 hours or 7 – 10 days post-
exercise, respectively (Egger et al. 1997a; Wang et al. 1993; Woodman et al. 1999; Laughlin et 
al. 2003).  Interestingly, continued stimulation with an exercise stimulus eventually results in a 
return to pre-training vasoreactivity level. However, animal models suggests that long term 
training results in repeated elevations of factors such as eNOS and other proteins such as 
vascular endothelial growth factor (VEGF) which may result in structural changes within the 
vasculature as a means to decrease shear stress. The adaptive responses might include 
restructuring of the vascular as a way to maintain flow at a more consistent rate (Prior et al. 
2003).  It is plausible that the vessels may remain dilated to decrease the shear stress or new 
vessels may be produced to provide adequate flow to regions with less vasoreactivity (Jasperse 
and Laughlin 2006; Prior et al. 2003).  These suggested timeframe of vascular changes are 
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consistent with the findings of this analysis in which changes in BAFMD are more significant in 
shorter exercise training interventions.  The longer exercise training interventions (> 8 weeks) 
may represent a time where vascular adaptations have occurred and thus explaining the only 
modest elevation in BAFMD. 
3.4.4 Limitations 
As with any meta-analysis conducted on existing study data, problems are inherent in the 
method.  Perhaps the most important problem that cannot always be overcome is that of 
publication bias.  Publication bias results from the fact that studies with significant results are 
more likely to be published than those with non-significant results (Egger and Smith, 1998). 
While the use of such analytical techniques as funnel plots helps to determine if publication bias 
is a problem in the meta-analysis, they do not rule out the fact that bias may be present in the 
analysis.  Without the inclusion of negative studies in the meta-analysis, the estimate for the 
overall effect size (and that of sub-group effect sizes as well) will be inflated.  Another problem 
that can lead to misleading results from meta-analysis is heterogeneity in the studies.  
Heterogeneity is inherent in any meta-analysis since all studies will differ in some 
characteristics.  While heterogeneity can be detected using statistical tests, these tests lack the 
power to detect anything but large differences in sub-group analysis (Egger et al. 1997b). 
Further, it should be noted that significant findings resulting from sub-group analysis should be 
seen as exploratory and not explanatory in nature.  An additional limitation of this meta-analysis 
includes the lack of true long term studies.  The studies available consisted of studies which 
examined exercise intervention from four to no greater than 24 weeks, thus limiting any 
conclusions on long term effects of exercise on BAFMD.  There was also an interest of the 
authors on examining training volume and changes in fitness measures; however, due to the large 
amount of differences between studies we were unable to develop a strategy to compare these 
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variables to BAFMD.  An additional limitation is the lack of understanding of the effect of blood 
flow velocity and its influence on BAFMD.  In fact, only six of the interventions analyzed 
reported blood flow velocity data.  This lack of data limits this meta-analysis in evaluating the 
effect of exercise on BAFMD as an effect of changes in the endothelium or whether the exercise 
has resulted in changes in blood flow velocity, a trigger for flow-mediated dilation.  It must also 
be noted that changes in BAFMD do not necessarily represent changes throughout the entire 
vasculature.  In fact, it has been shown that changes induced on the vasculature through exercise 
training are non-uniform (Jasperse and Laughlin, 2006) and may represent regional changes 
which may be dependent on the modality of exercise used during training (Allen et al. 2003). 
Many variables confound the measurement and interpretation of BAFMD; however, we still 
believe that BAFMD can be viewed as a screening tool to assess one’s potential vascular risk. 
3.5 Conclusion 
It is believed that BAFMD may be a biomarker for the degree and severity of endothelial 
dysfunction and, thus, has been proposed as a marker which can be used to assess the 
vasculature. Physical inactivity and disease adversely affect endothelial function. Although there 
are many papers published regarding the relationship of physical activity to BAFMD, there has 
been no clear consensus on the effect of exercise on BAFMD. In that regard, we performed this 
meta-analysis on published studies which examined the effect of exercise training on BAFMD, 
the ultimate purpose being to determine the effect of exercise interventions on BAFMD. 
On the basis of this meta-analysis, in exercise training interventions, BAFMD is a good 
biomarker which is capable of screening individual’s vascular risk and possesses sufficient 
sensitivity to detect changes during exercise training interventions.  This meta-analysis found 
that physical training does produce a large change in BAFMD.  Not only was the overall effect 
size large but in all the subgroup analyses, only one variable, resistance only training, did not 
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yield a significant effect size.  Of the 22 exercise training intervention groups, only one 
intervention study did not produce an increase in BAFMD.  It was observed that both healthy, 
and to a greater extent diseased subjects, had significant changes in BAFMD. This emphasizes 
the importance of exercise training as a primary prevention of CVD, as suggested by Booth et al. 
(2), and also secondary intervention as seen by the large changes in diseased subjects.  
Additionally, both length of training and type of training were significant moderators of 
BAFMD.  Exercise training intervention programs < 8 weeks showed the most significant 
changes thus indicating that improvements in vascular health occur quickly and long term 
exposure to exercise training may result in significant vasculature changes thereby decreasing the 
daily stress applied to the vasculature.  Likewise, similar to the suggestions of ACSM that a 
whole body exercise program is important in obtaining and sustaining maximal health benefits, 
this analysis found that both aerobic and/or a combination of aerobic and resistance training 
resulted in the largest changes in vascular reactivity.  Exercise training interventions result in 




INFLUENCE OF LONG-TERM ADHERENCE TO A LOW FAT DIET ON 
CARDIOVASCULAR RISK FACTORS:  ROLE OF GENETIC POLYMORPHISM 
 
4.1 Introduction 
To reduce risk of development of cardiovascular disease (CVD), the American Heart 
Association (AHA) has adopted a global approach to primary prevention and treatment of 
atherosclerosis.  In 2006, the AHA set forth both diet and lifestyle recommendations for 
atherosclerosis risk reduction in the general population (American Heart Association Nutrition 
Committee, 2006).  These recommendations place dietary modifications as the primary source of 
prevention.  The AHA suggests balancing calorie intake and physical activity to maintain a 
healthy body weight and consumption of diets which are high in fruits, vegetables, fish, and 
whole-grain, high fiber foods.  In addition, it suggests decreasing the intake of saturated fat to 
<7% of energy and trans fat to <1% energy, while consuming <300 mg of cholesterol per day.  
Additionally, there are some data that suggest even lower intakes of dietary fat which may 
decrease or potentially reverse the progression of vascular disease (Ornish et al. 1998; Ornish et 
al.1990; Barnard, 1991). 
Dietary interventions for CVD have focused on modifying total cholesterol (TC), low 
density lipoprotein-cholesterol (LDL-C), and high density lipoprotein-cholesterol (HDL-C) 
because elevated TC and LDL-C, as well as low HDL-C are risk factors associated with an 
increased risk of atherosclerosis.  Serum cholesterol levels are influenced by many factors 
including dietary fat and cholesterol intake, as well as genetic factors.  Attempts have been made 
to predict serum cholesterol responses to dietary intervention (Masson et al. 2003); however, in 
dietary interventions, lipid and lipoprotein responses are highly variable (Jacobs et al. 1983; 
McNamara et al. 1986; Schaefer et al.1997).   These relationships have led to many studies 
evaluating the average effects of low fat diets on risk factors and the morbidity and mortality of 
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CVD. Diets which focus predominantly on lowering dietary cholesterol and saturated fat 
typically decrease LDL-C; however, in some individuals, HDL-C levels are often lowered as 
well potentially increasing one’s risk (Nicolosi et al. 2001).  In these cases, this results in a 
failure to actually improve overall lipoprotein status and the ratio of TC to HDL-C (TC/HDL-C) 
or LDL-C to HDL-C (LDL-C/HDL-C) (Nicolosi et al. 2001). 
A key factor in the development of atherosclerosis is the apparent “health” of the vascular 
endothelium.  Because of the hypothesis that a breakdown in the vascular endothelial lining 
precedes atherogenesis, development of biomarkers and tests for vascular endothelial function, 
have emerged. A commonly used biomarker of this systemic vascular “health” is the brachial 
artery flow-mediated dilation (BAFMD) model. BAFMD has been proposed as a measurement 
of the degree and severity of cardiovascular disease (Corretti et al. 1995) and has been shown to 
be an independent prognostic measurement of patients with coronary artery disease (Bae et al. 
2004; Neunteufl et al. 2000; Gokce et al. 2002; Brevetti et al. 2003; Perticone et al. 2001; 
Modena et al. 2002; Fathi et al. 2004) and peripheral artery disease (Gokce et al. 2003). 
If BAFMD is a biomarker of vascular “health,” then one might ask how it responds to 
interventions aimed at modifying vascular risk.  In fact, a meta-analysis evaluating the effects of 
physical activity on BAFMD, found that physical activity, predominantly aerobic in nature, 
results in large improvements in vascular reactivity (Wilson et al. 2007).  However, dietary 
interventions, utilizing BAFMD as a biomarker of vascular “health,” are limited and 
predominantly only short term.  Results consistently show that acute responses to high fat meals 
(Cortes et al. 2006. Tushuizen et al. 2006; Ng et al. 2001) or meals prepared with used cooking 
fat (Williams et al. 1999) results in a transient decrease in BAFMD. However, only one long-
term dietary intervention study examining BAFMD has been reported in the literature which 
demonstrated that a low-saturated fat diet introduced in infancy and maintained during the first 
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decade of life was associated with enhanced endothelial function in boys (Raitakari et al. 2005).  
In contrast, results from calorie restricted diets over a short time period show conflicting findings 
(Brook et al. 2004; Raitakari et al. 2004; Jodoin et al.1999).  
One potential explanation for the conflicting findings in short term dietary interventions 
may be related to variability in individual responses.  In a review by Masson et al. (2003), it is 
suggested that there is evidence that the variability of lipid and lipoprotein responses to dietary 
interventions are largely due to differences in genes such as apo A-1, apo A-IV, apo B, and apo 
E.  However, even within specific genotypes, there appears to be heterogeneity in responses.  
Because many diseases, such as CVD, are likely to be related to both environmental and genetic 
interactions, it is important to appreciate the possibility that a global population intervention may 
not provide the most effective results to all individuals.  With an increased understanding of 
individual responses to interventions and the genetic influence on these responses, it may be 
possible to provide a modified environmental approach in the prevention of disease based on a 
“genetic profile” (Khoury et al. 2005). 
There are currently no studies in the literature that have reported the influence of a long-
term dietary intervention on BAFMD and the role that genetic polymorphisms may play on 
cardiovascular risk factors. Thus, this study seeks to examine, in a population of middle-aged, 
asymptomatic men and women with normal cholesterol levels, whether reductions in dietary 
total fat, saturated fat, and cholesterol will significantly alter biomarkers of vascular health and 
whether these changes are related to genetic variability. We hypothesized that long term 
adherence to a low fat diet will result in an improvement of cardiovascular risk factors including 
lipids, blood pressure, body mass index (BMI), body weight, body fat and BAFMD.  Secondly, 
that this low fat diet will result in groups of similarly responding individuals based on 
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biochemical and genetic factors; and finally, that these groups identified will have differences in 
the magnitude of the effect of BAFMD. 
4.2 Methods 
4.2.1 Experimental Design 
 This study was a prospective and randomized design consisting of a four-week baseline 
period and a two year dietary intervention with vascular data collected for the first year only. 
Participants were asked not to modify their eating habits during the initial four-week period.  
Those participants who successfully completed the pre-intervention period were randomized at a 
ratio of 2:1 to receive intensive instructions on how to substantially reduce dietary fat intake 
(Diet-intervention group) or generalized information on the Food Pyramid Guidelines (Control 
group). 
•Participants.  The REACH study at Pennington Biomedical Research Center recruited 
male and female volunteers between the ages of 45 and 64.  The participants had baseline age 
and gender adjusted mean LDL cholesterol levels between the 15th to 85th percentile, and HDL 
and triglyceride levels in the 5th to 95th percentile as defined by the NHANES II data (Carroll et 
al. 1993). The LDL values were the average of two fasting blood draws that were at least one 
week apart.  If a difference of ≥ 30 mg/dL was obtained between the two LDL values, a third 
analysis was performed and a mean of the three values taken.  Additional exclusions included a 
history of coronary artery disease (angina, myocardial infarction, abnormal ECG or abnormal 
stress test), diabetes mellitus, systolic pressure ≥ 160 mm Hg, or diastolic pressure ≥ 95 mm Hg, 
use of medications for treatment of elevated lipids or hypertension, body mass index > 35, use of 
tobacco products, or a history of drug or alcohol abuse.   
•Intervention Design. Diet-Intervention Group - Individuals in the diet-intervention arm 
received intensive dietary counseling consisting of group and individual sessions aimed at 
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achieving substantial reductions in the intake of total fat, saturated fat and cholesterol, while 
increasing the intake of complex carbohydrates. Nutritional goals were to reduce total fat to 15% 
of calories, saturated fat to 4% of calories, and cholesterol intake to less than 60mg/1000 Kcal. 
The counseling sessions were conducted by an experienced dietician, using a series of 
educational tools, including printed materials, videos, food models, diet scales, sample menus, 
and special recipe books. During the baseline period, sessions were directed towards acquiring 
participants’ usual eating habits. In addition, all participants were instructed on how to keep 
accurate food intake records. They were provided dietary scales and instructed in their use. 
During the final two weeks of the baseline period, group sessions were used that focused on the 
impact of diet on heart disease and general considerations of the evolution of heart disease, in an 
effort to orient the participant more fully to the impact of the diet design and its implications. 
Group sessions were limited to 12 to 15 participants and were approximately 1 to 2 hours in 
length. The first session following randomization was strictly devoted to a detailed 
description/introduction of the diet. Subsequent group sessions occurred weekly for two months, 
and every other week for the third and fourth month. For the remainder of the period group 
sessions were given on a monthly basis. In the event sessions were missed, provisions were made 
for a make-up session. Participants were encouraged to have their spouses, or significant other, 
attend the sessions. The emphasis of the sessions was to modify existing eating habits. Using 
information from the food intake records, the dietician would meet the participant and develop 
an individualized diet plan adapted to food preferences, dietary habits, and lifestyle. Additional 
food intake records were periodically obtained and reviewed to identify problems with 
compliance. Participants were provided progress graphs depicting changes in saturated fat and 
cholesterol intake, body weight, and blood cholesterol levels.  
   
 44
Control Group - No formal dietary counseling was provided to those in the control group.  
Selection of Diet-Compliant Subjects - Individual food intake records, food frequency 
questionnaires, and 24-hour diet recall data were reviewed at six months in order to ascertain the 
degree of dietary compliance.   
•Data Collection. Data were periodically collected over a two-year period for both the 
control and intervention arm subjects with most major end-point measurements examined for one 
year. The major end-points were collected at baseline and the end of the 3rd, 6th, and 12th month 
of the study. These included: 1) brachial artery diameters and reactivity before and after forearm 
occlusion; and 2) fasting lipid profiles. In addition, body weight, fasting glucose and insulin were 
examined at baseline and at the end of the 6th and 12th month. Participants’ diet intake was 
assessed at baseline and the end of the 3rd, 6th, and 12th month of the study through a 4-day food 
intake record, standardized food frequency questionnaires, and 24-hour diet recall.  
4.2.2 Methods 
•Anthropometric and Body Composition Measurements. Height and weight were 
assessed using standard clinical procedures.  
•Measurements of Brachial Artery Diameter and Reactivity.  All brachial artery imaging 
and analyses were conducted in accordance with the Guidelines set forth by the Brachial Artery 
Reactivity Task Force (Corretti et al. 2002).  Brachial artery ultrasound measures were obtained 
with participants in the supine position using a 7.5-MHz linear array transducer prior to, during 
and following 5 minutes of forearm occlusion.  Prior to scanning, participants were instructed to 
fast and refrain from exercise and alcohol intake for 12 and 48 hours, respectively.  Baseline 
ultrasound images were obtained after 20 minutes of supine rest.  All images were obtained in 
the longitudinal view, approximately 4 cm proximal to the olecranon process, in the 
anterior/medial plane.  Image depth was initially set at 4 cm, gain settings were adjusted to 
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provide an optimal view of the anterior and posterior intimal interfaces of the artery and kept 
constant throughout.   The participant’s arm was immobilized and slightly supinated.  Forearm 
occlusion consisted of inflation of a blood pressure cuff, positioned approximately 1 cm distal to 
the olecranon process, to 240 mm Hg for 5 min.  Images were obtained at rest and continuously 
from the final 30 seconds of occlusion until 5 minutes following the release of the blood pressure 
cuff. In addition, blood pressure and heart rate were monitored throughout the imaging process. 
All ultrasound images were recorded on compact discs for subsequent analysis.  
 Resting and peak brachial artery flow velocity measurements were obtained using a 
pulsed Doppler signal at an angle of approximately 60° to the vessel.  Resting velocities were 
determined following the initial 10 minutes of supine rest.  Peak brachial artery flow velocity 
was assessed immediately following release of the blood pressure cuff. 
Data were analyzed using Image Pro software (Media Cybernetics, Image-Pro Plus).  
Arterial diameters were calculated as the mean distance between the anterior and posterior wall 
at the blood vessel interface, with the image in diastole, defined as the peak of the r-wave.  Base 
diameter was defined by the average of 30 seconds of data obtained after 10 minutes of resting 
conditions. Peak dilation was defined (by visual inspection of the arterial diameter curve) as the 
largest diameter following release of the occluding cuff.  Its value was calculated by the average 
of 10 images (five seconds) surrounding this highest observable peak. BAFMD was defined as 
the peak dilation minus the base diameter x 100%/base diameter. 
•Blood Collection and Analyses. Subjects were fasting for 12 hours and had abstained 
from alcohol consumption 48 hours prior to collection.  With subjects in a sitting position, blood 
draws were obtained after the imaging procedure or on a subsequent day.    After aliquoting, 
samples were frozen at –80oC until analysis. Total cholesterol, triglycerides, and glucose were 
analyzed on the Beckman Synchron CX7 (Brea, CA) utilizing Beckman reagents and calibrators.  
Sigma Diagnostics (St. Louis, MO) EZ HDL Cholesterol reagent was used on the Beckman 
Synchron CX7 for HDL-cholesterol analysis. LDL-cholesterol (LDL-C) was calculated using the 
Friedewald equation. Plasma insulin analysis was performed on the Abbott IMx (Abbott Park, 
IL) utilizing Abbott IMx Insulin reagents, controls, and calibrators, respectively.  
Genomic DNA was isolated from buffy coats by the method of John et al. (1991). Based 
on evidence from the literature (Mason et al. 2003; Dreon et al. 1997; Ordovas et al. 1999; 
Schaefer et al. 1997) which have demonstrated that polymorphisms in select genes may affect 
the magnitude of lipid and lipoprotein response to low-fat dietary interventions, genetic 
polymorphisms in five select genes were examined. Individuals having either one or both copies, 
where the amino acid glutamine (Gln) has been substituted by a histidine (His) at position 360 in 
apolipoprotein A-IV (apolipoprotein A-IV (Gln360 His)), have shown larger decreases in HDL-
C during low-fat dietary intervention (Jansen et al. 1997).  Additionally, the replacement of a 
threonine (Thr) by a serine (Ser) at position 347 (apolipoprotein A-IV (Thr347 Ser)), a major 
apolipoprotein A-IV allele, has been associated with greater reductions in LDL-C with decreased 
intake of saturated fat (Ordovas et al. 1995; Jansen et al. 1997).  Therefore the prevalence of 
apolipoprotein A-IV (Gln360 His) and apolipoprotein A-IV (Thr347 Ser) were determined 
according to the methods described by Hixson et al. (1991).   The prevalence of apolipoprotein E 
(Arg158 Cys) (also known as apo E2) has been associated with a blunted response to low-fat 
dietary interventions (Kesaniemi et al. 1987; Dreon et al. 1995) and apolipoprotein E (Cys112 → 
Arg) (also known as apo E4) has been shown to be associated with a larger decrease in LDL-C 
but a smaller decrease in HDL-C during low-fat dietary interventions (Hagberg et al. 2000). 
Therefore, the prevalence of apolipoprotein E (Arg158 Cys) and apolipoprotein E (Cys112 → 
Arg) was determined according to the methods described by Hixson et al. (1990). Lastly, because 
individuals that are homozygous (two copies) for the deletion of three amino acids at the 
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apolipoprotein B signal peptide (apolipoprotein B signal peptide 27aa 24aa) have been 
associated with a larger decrease in HDL-C during low-fat dietary interventions (unpublished 
data from Pennington Biomedical Research Center, DAIRY study), the prevalence of 
apolipoprotein B signal peptide 27aa 24aa was determined according to the methods described 
by Xu et al. (1990). 
 •Food Intake Assessment. The 4-day food intake records were entered into a food diary 
program. This program is an adaptation of the MENu database designed specifically for analyses 
of food intake records. Entries were verified to assure the codes used were appropriate. After 
verification, the program generated an output detailing the following nutrients amounts and/or 
percentages: kilocalories, protein, carbohydrate, fat, saturated fat, monounsaturated fat, 
polyunsaturated fats, total dietary fiber, and vitamins and minerals of interest.  
4.2.3 Statistical Analysis 
Statistical analyses were performed using SPSS for Windows (version 11.0). Baseline 
data were evaluated utilizing analysis of variance.  Dietary compliance between the diet-
intervention group and the control group for self-reported daily calories, total fat intake, total 
saturated fat intake, and cholesterol intake was tested utilizing repeated measures analysis of 
variance and analysis of variable by comparing the on-trial average (average of month 3, 6, and 
12) change from baseline (on-trial average minus baseline).  
Each end-point variable was tested at baseline and months 3, 6, and 12, except for blood 
pressure, which was monitored at baseline, month 6, and month 12. Variables examined were 
serum lipids, TC/HDL-C ratio, LDL-C/HDL-C ratio, serum glucose, blood pressure, and 
vascular markers (BAFMD and resting brachial diameter). Each variable was tested for 
differences in time course between groups (diet-intervention and controls) by assessing the main 
effect of time and the group x time interaction. For variables with significant changes over time, 
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either Games-Howell, for variables with significant homogeneity of variance, or Tukey HSD 
post hoc multiple comparisons were used.   
Cluster analysis was performed on the programs, Cluster (version 2.11) and TreeView 
(version 1.6) written by Michael Eisen.  Cluster groups were created using uncentered 
hierarchical cluster analyses using average linkage clustering of repeated measures of risk factors 
with normalized arrays and median centered arrays based on changes in lipids, body mass index, 
glucose, and BAFMD. Cluster analysis is a classification method that mathematically sorts 
objects into groups that maximize the degree of association.  The algorithm assembles the data 
into a dendogram which resembles a tree with the most closely related (correlated) or similarly 
responding entries placed into the closest branches.  As dissimilar entries are added to the tree, 
additional branches are added.  This process produces larger and larger clusters of items or 
individuals (Eisen et al. 1998). Groups were produced and selected based on a correlation value 
of approximately 0.50 with no overlapping individuals (Crispino et al. 2007).  Group differences 
were tested using a repeated measure analysis of variance covarying for age and/or gender when 
statistically significant for serum lipids, glucose, insulin, and blood pressure. Average on-trial 
changes in total cholesterol, HDL-C, LDL-C, triglycerides, glucose, insulin, and blood pressure 
in the diet intervention group were analyzed by genotypes.  Additionally, the genetic frequencies 
of the analyzed polymorphisms for each cluster were determined.  However, due to insufficient 
numbers in all categories, chi-square was deemed invalid.  
Lastly, group differences between clusters were tested using a repeated measure analysis 
of variance for BAFMD.  Additionally, average on-trial changes in BAFMD in the diet 
intervention group were analyzed by genotypes.   
An alpha level of ≤ 0.05 was considered statistically significant.  Data were presented as 
mean ± standard deviation. 
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4.3 Results 
4.3.1 Participant Characteristics 
Baseline characteristics and dietary intake for all the participants are shown in Table 4.1. 
Approximately 90% of the participants were Caucasian and almost two-thirds of the participants 
were female. The study population was a representation of a middle-aged population with lipid 
levels in the normal range. Similarly, intakes of total fat, saturated fat, and cholesterol, as 
assessed by four day food intake record, were representative of the US population (average of 
male and female values for ages 50 to 59) as determined by the 1996 Continuing Survey of Food 
Intakes by Individuals (CSFII). The mean age and LDL-C were statistically significantly 
different between the diet-intervention and the control groups. There were no other statistically 
significant pre-intervention differences for any other variables. 
4.3.2 Impact of Dietary Intervention on Macronutrient Intake 
Table 4.2 depicts the daily intake of calories, total fat, saturated fat, and cholesterol for 
both the diet-intervention group and the controls as determined by four day food intake records 
over the 12 month period. Participants reported similar intakes at baseline.  However, 
participants in the diet-intervention group reported significantly lower intake in daily calories, 
total fat and saturated fat, and cholesterol at month 3 and each subsequent follow-up point during 
the intervention versus baseline (p<0.001) and relative to the control group (p<0.001). No 
differences in reported intakes were noted in the diet intervention group between the follow-up 
points.  Subsequently, Table 4.3 shows the reported on-trial average intakes and change from 
baseline. The average on-trial differences between the groups for total fat, saturated fat, and 
cholesterol intake as estimated by the four day food intake records were ~11%; ~4%%; and  ~60-
70 mg/day, respectively. These results indicate that participants in the diet-intervention group 
reportedly achieved significant reductions in total fat intake, although not the targeted intake of 
15%, 4%, and less than 60 mg/1000 kcals, respectively. 
Table 4.1 
Baseline Participant Characteristics and Dietary Intake 
 
Variable Means SD Mean SD
Age (years)* 55.8 5.3 54.3 5.2
DBP (mm Hg) 75.6 6.7 76.5 6.7
SBP (mm Hg) 122.3 14.0 122.9 16.4
Weight (kg) 77.3 15.3 76.7 14.7
Body Fat (%) 38.3 9.5 38.3 9.4
TC (mg/dL) 221.2 28.0 215.0 22.8
HDL-C (mg/dL) 58.4 13.1 58.9 14.3
LDL-C (mg/dL)* 136.9 24.4 130.1 21.3
TC/HDL-C (mg/dL) 4.0 0.9 3.9 1.0
LDL-C/HDL-C (mg/dL) 2.5 0.7 2.4 0.8
Triglycerides (mg/dL) 131.2 64.0 131.5 72.4
Body Mass Index (kg/m2) 27.4 4.2 26.9 4.2
Glucose (mg/dL) 98.5 8.3 99.8 7.8
Insulin (ln uU/mL) 1.9 0.6 1.9 0.5
BAFMD (%) 5.1 3.5 5.5 2.8
Brachial artery diameter (mm) 3.3 0.6 3.3 0.6
Total Fat Intake (% of energy) 31.3 7.6 31.6 6.2
Saturated Fat Intake (% of energy) 9.6 2.8 9.9 2.9
Cholesterol Intake                                 
(mg/day; adjusted for calories) 139.2 52.6 145.8 50.7
















4.3.3 Impact of Dietary Intervention on Biochemical, Body Weight, Body Fat and Vascular 
Markers  
Table 4.4 shows the serum lipids and glucose, blood pressure, and vascular end-points of 
both the diet-intervention group and the controls over the course of 12 months.  Total cholesterol 
(0-3 month, p=<0.001; 0-6 month, p=<0.001; 0-12 month, p=0.004) and LDL-C (<0.001 at all 
time points) decreased significantly in the diet-intervention group.  Figure 4.1a and  
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Time Group x Time
Variable Means SD Mean SD
Daily Calories (kcal) <0.001 <0.001
Baseline 1870.6 495.8 1835.8 533.4
Month 3 1511.6 441.0 1746.6 536.7
Month 6 1527.9 452.6 1751.6 529.8
Month 12 1548.5 480.2 1717.2 515.7
Total Fat Intake                   
(% of energy) <0.001 <0.001
Baseline 31.2 7.6 31.4 6.1
Month 3 18.7 6.6 32.2 7.2
Month 6 19.0 6.7 33.1 7.5
Month 12 19.8 7.2 31.6 7.4
Total Saturated Fat Intake 
(% of energy) <0.001 <0.001
Baseline 9.52 2.85 9.87 2.84
Month 3 5.48 2.41 9.85 2.88
Month 6 5.56 2.27 10.36 3.05
Month 12 5.80 2.41 10.12 2.82
Cholesterol Intake (mg/day; 
adjusted for calories) 0.04 <0.001
Baseline 259.77 94.45 266.46 93.34
Month 3 214.49 69.74 276.04 93.14
Month 6 208.43 70.17 283.36 102.92
Month 12 205.04 71.00 280.84 103.59
1Testing for change over time (main effect of time) and difference in time course between groups (group x time interaction) 
using Wilks' Lambda.  Repeated-measures ANOVA was used to account for within-subject correlations.
Group p1
Low-fat Diet Controls
(n = 136) (n = 68)
Table 4.3 On-Trial Averages and Change from Baseline for Dietary Variables between the Low-
Fat Diet Intervention Group and the Controls 
 
Variable Means SD Mean SD
Total Fat Intake - On-Trial Average           
(% of energy) 19.3* 5.8 32.7 6.5
Saturated Fat Intake - On-Trial Average      
(% of energy) 5.7* 2.1 10.3 2.6
Cholesterol Intake - On-Trial Average 
(mg/day; adjusted for calories) 209.5* 56.7 281.4 79.3
Total Fat Intake -                                 
(Change in % of energy) -12.0* 7.2 1.4 5.6
Saturated Fat Intake -                         
(Change in % of energy) -3.9* 2.7 0.4 2.2
Cholesterol Intake -                          
(Change in mg/day adjusted for calories) -49.1* 82.8 13.7 92.4
*p < 0.001










Table 4.4 Outcome Variables over 12 months 
 
Time
Variable Means SD Mean SD
<0.001
Baseline 221.2 28 215 22.8
Month 3 204.4 30.2 209.8 26.6
Month 6 207.6 28.2 212.8 26.7
Month 12 209.7 28.6 216 28.3
Baseline 136.9 24.4 130.1 21.3
Month 3 122.1 24.2 125.8 23.7 <0.001
Month 6 122.9 24.1 129.3 23.3
Month 12 124.1 24.6 130.7 24.7
HDL-C (mg/dL)
Baseline 58.4 13.1 58.9 14.3
Month 3 55.2 12.6 59.2 14.7 <0.001
Month 6 56.2 12.5 59.1 14.5
Month 12 57.3 12.9 60.5 16.7
Baseline 3.96 0.92 3.85 0.97
Month 3 3.85 0.84 3.74 0.95 <0.001
Month 6 3.85 0.86 3.79 0.98
Month 12 3.82 0.93 3.81 1.07
Baseline 2.47 0.73 2.36 0.77
Month 3 2.31 0.60 2.27 0.77 <0.001
Month 6 2.29 0.66 2.34 0.79
Month 12 2.28 0.73 2.35 0.87
Triglyceride (mg/dL)
Baseline 131.2 64.0 131.5 72.4
Month 3 135.6 67.0 124.5 69.0 0.669
Month 6 143.7 68.1 123.3 57.1
Month 12 143.6 72.5 124.3 60.8
Glucose (mg/dL)
Baseline 98.54 8.35 99.78 7.82
Month 3 97.89 8.63 99.72 8.07 0.25
Month 6 97.48 7.57 100.76 8.49
Month 12 96.56 7.26 96.56 7.26
Weight (kg)2
Baseline 77.25 15.3 76.65 14.7
Month 6 74.94 14.9 76.79 14.8 <0.001
Month 12 75.14 15.4 77.27 15.4
Body Fat (%)
Baseline 38.3 9.5 38.3 9.4
Month 6 36.4 9.8 38.3 9.4 <0.001
SBP (mm Hg)
Baseline 121.2 12 121.8 12.7
Month 6 121.4 11.9 120.4 12.7 0.42 0.41
Month 12 122 12.9 121.2 10.8
DBP (mm Hg)
Baseline 75.6 6.7 76.5 6.7
Month 6 75.3 6.9 75.7 6.9 0.3 0.08
Month 12 74.7 7.1 76.7 6.8
BAFMD (%)
Baseline 5.14 3.59 5.56 2.67
Month 3 6.53 3.83 7.09 3.38 <0.001 0.457
Month 6 6.61 3.85 7.16 4.17
Month 12 6.14 3.84 7.35 3.35
Baseline 3.27 0.63 3.19 0.57
Month 3 3.2 0.6 3.12 0.54
Month 6 3.17 0.6 3.11 0.57 <0.001 0.75
Month 12 3.2 0.61 3.15 0.57




















4.1b shows the changes in TC and LDL-C across the trial for both groups. The figure provides 
clear evidence that the greatest magnitude of change in the diet-intervention group occurred 
within the first 3-months of the trial without significant relapse across the remainder of the trial. 
Figure 4.1c indicates that in the diet-intervention group, HDL-C decreased significantly at the 3 
month follow-up period.  However, no significant differences in HDL-C were noted for the 6 and 
12 month follow-up periods, compared to baseline. Figures 4.1d and 4.1e report the changes in 
the TC/HDL-C and LDL-C/HDL-C ratio across the intervention period of both groups. In both 
groups there was an initial reduction in the lipid ratios at 3 months.  However, the reductions in 
lipid ratios were maintained throughout the remainder of the trial in the diet-intervention group, 
only.  Importantly, only the changes for the LDL-C/HDL-C ratio across the intervention period 
were significantly different between the groups. Additionally, the diet-intervention group had a 
significant decrease in both body weight and body fat while the control group remained stable. 
In regards to the vascular measures, BAFMD increased significantly and brachial artery diameter 
decreased across the intervention period, in both groups.  These changes are shown in Figures 
4.1f and 4.1g.  Clearly, the greatest change in BAFMD and brachial artery diameter occurred by 
month 3. In an effort to further explore possible diet intervention effects; various study 
population and dietary stratifications with the change in BAFMD as the dependent measure were 
defined.  The results of the effect of population and dietary stratification on the change in 
BAFMD were examined.  No treatment effect was evident.  However, the data do reveal an 
interesting relationship between the on-trial changes in BAFMD and the changes in percent body 
fat when comparing those with the largest change (third tertile) to those with the smallest change 
(first tertile) in percent body fat (∆ body fat, -3.7 ±1.8 vs. 1.3 ± 1.3%; ∆ BAFMD, 1.8 ± 2.9 vs. 
0.9 ± 2.9%; p < 0.001). 
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Figure 4.1 Lipid and BAFMD values over 12 month period for controls and diet-
intervention group. a) Total cholesterol, b) LDL-C, c) HDL-C, d) TC/HDL-C Ratio, 
e) LDL-C/HDL-C, f) BAFMD, and g) Brachial artery baseline diameter 
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Figure 4.2 On-Trial % Change in BAFMD when initial BAFMD is < 3%, between 3-6%, and    
> 6% as compared to the on-trial change in body fat (%) in men 
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Figure 4.3 On-Trial % Change in BAFMD when initial BAFMD is < 3%, between 3-6%, and    
> 6% as compared to the on-trial change in estimated energy intake (kcals) in men 
 
Upon closer examination, this relationship was particularly interesting in men, as shown 
in Figure 4.2. In particular, those individuals with the greatest fat loss over the course of the 
study also had the greatest gains in BAFMD if their vasoreactivity was less than 6% prior to the 
intervention. This association was also apparent for the association between the on-trial changes 
in BAFMD and the reported caloric intake (Figure 4.3). 
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Finally, there were no statistically significant changes over time in triglycerides or 
glucose in the diet-intervention group or the control group. No changes were noted in any other 
hemodynamic measures, including blood pressure and heart rate. 
4.3.4 Dietary Intervention Production of Clusters and Differences in Biochemical Responses, 
Changes in Body Mass Index, and Brachial Artery Diameters and Reactivity 
The results of the hierarchical cluster analyses are presented in the dendogram in Figure 
4.3.  The cluster analysis revealed six (6) distinct non-overlapping groups.  Table 4.5 shows the 
biochemical and vascular responses over the 12 month study for the clusters and Table 4.6 shows 
the changes in macronutrients over the course of the study.  Cluster 1 had 23 diet-intervention 
participants and 37 control participants (r=0.497) which constituted 53% of the control group but 
also 17% of the diet-intervention group.  Cluster 2 consisted of 14 diet-intervention and 7 control 
participants (r=0.535).  Cluster 3 consisted of a large group of participants, 23 diet-intervention 
and 15 control participants, falling at the center of the tree with a low correlation (r=0.227) due 
to there varied responses as compared to other clusters.  Clusters 4 (r=0.61), 5 (r=0.608), and 6 
(r=0.521) constituted 55% of the diet-intervention group with only 2 control participants in 
cluster 4 and 8 control participants in Cluster 6. The cluster analysis revealed significant changes 
over time and between cluster groups for TC, LDL-C, HDL-C, triglycerides, TC/HDL-C, LDL-
C/HDL-C, glucose, and insulin.   
The analysis also revealed a significant change over time for brachial artery diameter and 
BAFMD (p= <0.001). However, there were no significant differences between clusters.  Systolic 
blood pressure showed no changes over time, whereas diastolic blood pressure showed only a 
modest change over time (p=0.044) but was not different between clusters. 
There was a significant difference over time and between clusters for reported total 
calories intake, percent fat intake, and saturated fat intake.  There was a significant change over 
time for reported cholesterol intake; however, there was not a significant difference between 
groups. 
Figure 4.4 provides an overview of the changes in a select number of biochemical, 
hemodynamic, and vascular variables per cluster.  The changes for Cluster 1 were most 
remarkable for an increase in HDL-C, and a decrease in the lipid ratios TC/HDL-C and LDL-
C/HDL-C. Changes for Cluster 2 were significant for a decrease in TC, LDL-C, TC/HDL-C and 
LDL-C/HDL-C, triglycerides, and insulin, and an increase in BAFMD. Cluster 3 changes were 
most significant for a decrease in HDL-C, and glucose, and an increase in BAFMD. Changes for 
Cluster 4 were most significant for a decrease in TC, LDL-C, TC/HDL-C and LDL-C/HDL-C, 













Figure 4.3 Dendogram from Hierarchical Cluster Analysis showing the six non-overlapping 
groups. 
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Table 4.5 Cluster Analysis Groups Biochemical and Vascular Responses over a 12 month period
Cluster Correlation
Low Fat/Controls (n)
Variable Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Time
<0.001 <0.001
Baseline 210.38 23.36 222.10 30.2 214.55 22.2 225.68 25.7 202.58 27.9 231.24 24.9
Month 3 211.35 29.63 200.76 28.3 207.14 24.3 192.74 25.7 205.54 28.8 214.05 34.4
Month 6 211.22 25.01 206.69 30.9 214.96 26.5 200.37 23.8 200.31 29.5 214.68 33.9
Month 12 218.07 25.86 203.06 28.4 212.52 26.4 205.56 29.9 210.58 36.5 213.91 30.9
Mean Change 3.08 -18.49 -2.68 -25.99 2.79 -17.10
Mean % Change 1.46 -8.32 -1.25 -11.51 1.38 -7.40
HDL-C (mg/dL) <0.001 <0.001
Baseline 58.77 14.15 54.85 13.9 56.96 12 57.96 13.5 54.79 8.36 62.49 13.2
Month 3 61.55 14.46 53.22 13.3 55.15 11.4 51.06 10.5 53.31 9.47 56.36 14.2
Month 6 61.11 14.81 54.08 12.3 55.85 11.3 52.95 10.9 52.48 8.45 57.18 14.2
Month 12 63.02 16.52 55.09 13.6 54.63 11.7 55.52 12.5 55.81 10.4 56.88 13.5
Mean Change 3.12 -0.73 -1.75 -4.78 -0.93 -5.68
Mean % Change 5.31 -1.32 -3.08 -8.25 -1.69 -9.09
LDL-C (mg/dL)2 <0.001 <0.001
Baseline 125.62 21.43 135.09 31 130.94 20.6 140.98 19.2 126.98 22.6 147.23 22.7
Month 3 125.75 24.97 125.30 26.8 124.32 23.2 114.00 17.3 123.58 25 129.95 24.3
Month 6 124.75 20.46 127.65 31 132.16 25.4 116.46 19.2 119.31 23.4 130.89 25.3
Month 12 129.54 22.02 124.99 26.8 130.92 27 119.65 24.2 124.53 28.3 129.67 23.8
Mean Change 0.98 -8.95 -1.76 -24.15 -4.65 -17.12
Mean % Change 0.78 -6.63 -1.35 -17.13 -3.66 -11.63
0.001 <0.001
Baseline 3.77 1.0 4.24 0.9 3.95 1.0 4.06 0.9 3.75 0.7 3.85 0.9
Month 3 3.59 0.9 3.92 0.7 3.95 1.1 3.89 0.7 3.96 0.8 3.95 0.8
Month 6 3.61 0.8 3.93 0.7 4.06 1.2 3.93 0.9 3.88 0.7 3.92 0.9
Month 12 3.64 0.8 3.84 0.9 4.13 1.3 3.87 1.0 3.87 0.9 3.92 0.9
Mean Change -0.15 -0.34 0.09 -0.16 0.15 0.08
Mean % Change -4.10 -8.05 2.32 -4.02 4.03 1.98
<0.001 0.005
Baseline 2.28 0.8 2.59 0.7 2.44 0.8 2.56 0.7 2.36 0.5 2.49 0.8
Month 3 2.16 0.7 2.43 0.6 2.39 0.8 2.32 0.5 2.39 0.6 2.44 0.7
Month 6 2.16 0.6 2.43 0.5 2.52 0.9 2.30 0.7 2.32 0.6 2.43 0.7
Month 12 2.20 0.7 2.36 0.7 2.57 1.0 2.28 0.8 2.30 0.7 2.41 0.7
Mean Change -0.11 -0.18 0.05 -0.26 -0.03 -0.07
Mean % Change -4.84 -7.06 2.04 -10.25 -1.14 -2.77
Triglyceride (mg/dL) 0.033 <0.001
Baseline 131.65 74.8 168.74 89.9 133.27 59.1 133.69 60.2 104.04 35.3 107.62 52.6
Month 3 120.25 68.0 111.19 51.8 138.32 72.1 138.38 58.5 143.23 60.2 138.73 78.0
Month 6 128.28 59.5 124.79 66.2 137.01 63.1 157.01 78.1 142.62 56.9 133.00 65.6
Month 12 127.56 58.9 118.38 71.8 138.09 67.8 155.66 75.8 151.15 72.5 138.42 72.8
Mean Change -6.28 -50.62 4.54 16.66 41.63 29.10
Mean % Change -4.77 -30.00 3.41 12.46 40.01 27.03
Glucose (mg/dL) <0.001 <0.001
Baseline 97.45 7.0 97.76 6.6 104.92 8.1 100.39 8.3 103.62 9.4 94.49 6.9
Month 3 99.08 7.9 98.67 8.5 99.38 9.2 98.30 8.4 101.62 8.0 96.22 8.9
Month 6 100.33 8.3 99.52 9.7 96.86 7.8 99.70 8.3 100.00 8.4 95.35 6.6
Month 12 99.37 7.6 97.38 7.7 98.92 7.9 97.15 7.5 99.08 7.5 94.68 7.8
Mean Change 2.14 0.76 -6.53 -2.01 -3.38 0.93
Mean % Change 2.20 0.78 -6.23 -2.00 -3.27 0.98
Insulin (ln uU/mL) <0.001 <0.001
Baseline 1.82 0.4 2.10 0.5 1.92 0.7 2.17 0.5 2.07 0.5 1.69 0.4
Month 3 1.75 0.5 1.87 0.4 1.84 0.7 2.17 0.5 1.82 0.5 1.87 0.5
Month 6 1.84 0.5 1.92 0.6 1.93 0.6 1.99 0.4 1.79 0.5 1.87 0.5
Month 12 1.96 0.4 2.00 0.5 1.93 0.6 2.07 0.4 1.94 0.5 1.98 0.5
Mean Change 0.03 -0.17 0.07 -0.20 -0.22 0.22
Mean % Change 1.87 -8.10 3.65 -9.18 -10.69 12.83
SBP (mm Hg) 0.172 0.223
Baseline 120.38 12.7 125.11 15.3 116.54 9.9 122.93 11.9 126.27 10.9 123.51 11.5
Month 6 121.05 12.9 122.05 14.3 118.50 10.3 121.66 10.8 126.27 14.0 120.36 11.4
Month 12 120.95 11.0 123.61 15.7 119.00 9.4 121.49 10.8 129.23 16.5 122.39 12.8
Mean Change -0.62 -0.79 0.88 -1.35 -2.77 -0.80
Mean % Change -0.51 -0.63 0.75 -1.10 -2.19 -0.65
DBP (mm Hg) 0.044 0.412
Baseline 76.31 6.4 76.75 9.4 74.13 5.9 76.11 7.2 74.85 6.0 76.70 6.6
Month 6 75.60 6.9 76.19 9.1 74.81 6.2 75.18 6.3 71.50 4.6 76.03 7.1
Month 12 75.78 6.3 75.74 8.9 75.28 6.7 74.38 6.6 72.65 6.4 75.74 7.8
Mean Change 0.62 -2.28 2.28 -1.17 1.48 -2.04
Mean % Change 0.81 -2.97 3.08 -1.53 1.98 -2.65
BAFMD (%) <0.001 0.213
Baseline 5.81 3.7 6.26 3.4 4.48 3.0 5.53 3.0 5.21 3.6 4.46 3.0
Month 3 7.37 3.5 8.05 4.0 6.67 4.0 6.56 4.1 6.08 1.8 5.54 3.8
Month 6 6.83 4.0 8.53 4.1 6.61 3.5 6.43 4.2 6.78 3.4 6.74 3.8
Month 12 6.65 3.4 7.94 4.7 7.54 3.7 5.66 3.8 5.40 4.1 5.65 3.2
Mean Change 1.14 1.91 2.46 0.68 0.87 1.52
Mean % Change 19.54 30.51 54.78 12.38 16.75 34.11
<0.001 0.213
Baseline 3.15 0.5 3.30 0.7 3.10 0.5 3.41 0.6 3.51 0.6 3.21 0.6
Month 3 3.05 0.5 3.30 0.7 3.10 0.5 3.42 0.6 3.38 0.4 3.15 0.6
Month 6 3.06 0.5 3.15 0.6 3.08 0.5 3.36 0.7 3.40 0.5 3.05 0.6
Month 12 3.11 0.5 3.25 0.6 3.08 0.5 3.40 0.7 3.39 0.6 3.08 0.6
Mean Change -0.08 -0.12 -0.01 -0.02 -0.12 -0.11
Mean % Change -2.53 -3.52 -0.26 -0.53 -3.48 -3.50
2Covaried for gender
0.535





1Testing for change over time (main effect of time) and difference in time course between groups (group x time 
interaction) using Wilks' Lambda.  Repeated-measures ANOVA was used to account for within-subject correlations.
Cluster 5 Cluster 6
LDL-C/HDL-C (mg/dL)2















Table 4.6 Cluster Analysis Groups Macronutrient Changes over a 12 month period 
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nth 12 248.2 80.6 262.9 112.3 253.6 100.3 185.8 49.1 221.1 78.0 218.1 108.7
Mean Change -18.0 -6.8 -12.7 -78.3 -25.3 -34.8
Mean % Change -6.4 -2.5 -4.9 -28.9 -10.9 -14.5
Cholesterol Intake           (mg/day; 
adjusted for calories)










Cluster 2 Cluster 3
0.227
Cluster 5 Cluster 6




















Variable Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Time
Daily Calories (kcal) <0.001 0.019
Baseline 1782.4 501.8 2042.4 542.6 1841.6 414.6 2033.8 622.4 1836.5 394.4 1829.9 479.1
Month 3 1602.9 491.9 1451.2 531.9 1623.6 445.2 1627.6 549.3 1487.9 389.3 1688.4 450.5
Month 6 1608.3 492.7 1537.3 564.0 1619.5 447.4 1646.0 542.7 1544.5 369.2 1660.2 466.2
Month 12 1589.8 517.1 1457.1 396.9 1614.7 411.7 1720.5 615.4 1644.1 501.8 1629.6 437.4
Mean Change -182.1 -560.6 -222.4 -369.1 -277.7 -170.5
Mean % Change -10.2 -27.4 -12.1 -18.1 -15.1 -9.3
Total Fat Intake           
(% of energy) <0.001 <0.001
Baseline 31.8 6.8 33.5 7.2 31.0 6.3 33.5 7.1 27.8 8.5 30.3 6.9
Month 3 28.6 8.7 25.3 10.0 24.5 9.6 16.8 5.4 16.9 6.0 20.5 8.8
Month 6 30.0 9.6 25.7 9.2 24.8 9.1 17.6 6.3 16.6 4.4 20.9 8.7
Month 12 28.1 8.5 26.7 10.8 24.5 8.7 17.5 6.8 18.7 6.8 21.9 8.6
Mean Change -2.9 -7.7 -6.4 -16.3 -10.4 -9.2
Mean % Change -9.0 -22.8 -20.7 -48.5 -37.4 -30.4
<0.001 <0.001
Baseline 9.7 3.0 10.8 3.2 9.5 2.3 10.7 2.8 8.2 2.3 9.3 2.9
Month 3 8.8 3.2 8.2 4.3 7.3 3.2 4.9 1.9 4.4 1.6 6.0 2.8
Month 6 9.5 3.7 7.5 2.9 7.4 3.2 5.1 2.0 4.7 1.6 6.3 2.9
Month 12 8.9 3.1 7.8 3.9 7.5 3.3 5.1 2.1 5.4 1.8 6.7 3.3
Mean Change -0.7 -2.9 -2.1 -5.7 -3.4 -2.9
Mean % Change -6.9 -27.3 -21.7 -53.2 -41.2 -31.5
0.002 0.102
Baseline 281.1 101.1 274.3 101.8 262.1 103.0 271.2 102.2 230.9 77.0 239.6 75.0
Month 3 272.1 86.7 276.0 90.9 242.0 76.5 199.5 63.3 192.7 39.4 197.5 81.3
Month 6 269.2 101.9 263.6 102.0 252.5 78.7 193.3 70.4 203.2 36.2 198.8 77.0
 Mo
 
an increase in TC/HDL-C and triglycerides, and a decrease in insulin. Finally, the most notable 
changes for Cluster 6 were seen in a decrease in TC, HDL-C, LDL-C, and an increase in 
triglycerides, insulin, and BAFMD.  
In summary, the observed changes were quite varied between the clusters, with perhaps 
the most favorable changes noted in Cluster 2. Cluster 3 appears to have the least changes. In 
























Figure 4.4 Overview of Changes in Lipids and Vascular Markers by Cluster 
a. Cluster 1, b. Cluster 2, c. Cluster 3, d. Cluster 4, e. Cluster 5, f. Cluster 6 (TC – total 
cholesterol; LDL-C – low density lipoprotein cholesterol; HDL-C – high density 
lipoprotein cholesterol; Trig – triglyceride; Glu – glucose; BAFMD – brachial artery flow 











































































































































































Figure 4.4 Cont’d 
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4.3.5 Role of Genetic Polymorphisms 
The data presented in Table 4.7 includes the gene-diet interactions for all participants in 
the diet-intervention group.  For all polymorphisms except the apolipoprotein B signal peptide,  
where sufficient numbers for each genotype existed, homozygous and heterozygous individuals 
for the rarer allele were combined into a single group for analysis.   
The data showed the frequency of a cystine (Cys) at position 158 and an arginine (Arg) at 
position 112 of the apolipoprotein E gene was 17% and 24% respectively.  In regards to the 
apolipoprotein A-IV gene, histidine (His) was present at position 360 with a frequency of 21% 
and serine (Ser) at position 347 was found to have frequency of 31%.  Lastly, the deletion of 
three amino acids resulting in a 24 amino acid product at the apolipoprotein B signal peptide had 
a frequency of 39%.There were no statistical differences between genotypes and biochemical 
and vascular responses for apolipoprotein E (Cys158) or apolipoprotein E (Arg112).  Apo A-IV 
(His360), however, showed a reduction, rather than an increase, in triglycerides in individuals 
with at least one apolipoprotein A-IV (His360).  There was a significantly greater reduction in 
HDL-C in individuals with the apolipoprotein A-IV (Ser347) allele.  There were no significant 
differences in BAFMD with the analyzed genotypes. The genetic frequencies of the analyzed 
genetic polymorphisms evaluated by clusters are presented in Table 4.8.  Due to insufficient 
numbers in the clusters, chi-square results are not reported.  Cluster 1 had the highest frequency 
of the apolipoprotein E (Cys158) allele and cluster 5 had the highest frequency of the 
apolipoprotein E (Arg112) allele.  Cluster 2 had the greatest frequency of both the apolipoprotein 
A-IV (His360) and (Ser347) alleles.  Finally, clusters 4 and 6 had the highest frequency of the 





The findings of this study indicate that adherence to a low fat diet for 12 months result in 
small but statistically significant improvements in some cardiovascular risk factors including 
lipid balance (as defined by the LDL-C/HDL-C), weight, BMI, and body fat percentage. In 
contrast, no such changes were observed for glucose, insulin, and blood pressure, whereas 
vasoreactivity (defined as BAFMD) improved significantly in both the intervention and control 
groups.  
In addition, the hierarchical cluster analyses revealed six distinct groups, with some 
groups showing favorable changes, but other groups revealing negative changes to the diet 
intervention, which were in part influenced by certain genetic polymorphisms (in particular the 
apolipoprotein A-IV (His360) allele, and the apolipoprotein A-IV (Ser347) allele). However, any 
group differences were generally quite small. Moreover, no differences in the magnitude of the 
effect of the diet were noted for BAFMD for any of the identified clusters. These data suggest 
that a long-term low-fat diet aimed at reducing cardiovascular risk factors in middle-age men and 
women, with normal cholesterol levels and without overt disease, provides little benefit. Finally, 
the magnitude of the effect of the diet was minimally influenced by biochemical and genetic 
factors.  
4.4.1 Impact of Dietary Intervention on Macronutrient Intake 
The nutrient targets (i.e. a reduction in total fat intake to 15% of calories, saturated fat to 
4% of calories, and cholesterol intake to less than 60mg/1000 Kcal) for the current study were 
similar to those used in other clinical trials (Henderson et al. 1990; Lee-Han et al. 1988; Heber et 
al. 1992; Walden et al. 1991; Brown et al. 1984; Thuesen et al. 1986). The nutrient targets for the 
current study were not met, suggesting that the participants found it difficult to decrease intake of 
foods containing saturated fat and cholesterol. Importantly, the reductions that were achieved 
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/dL) -12.7 15.2 -9.1 17.2 -11.7 14.6 -13.3 18.4 -11.7 16.0 -13.5 14.3 -11.5 14.8 -13.3 17.3 -10.6 15.7 -12.3 14.7 -15.4 18.0
HDL-C (mg/dL) -1.7 5.1 -1.7 4.8 -1.7 4.9 -1.9 5.7 -1.9 5.1 -1.3 5.2 -1.2 5.0 -3.0† 5.0 -1.2 4.1 -1.5 4.9 -3.8 7.3
LDL-C (mg/dL) -12.2 14.0 -9.6 13.8 -11.6 13.8 -12.3 14.5 -11.9 14.6 -11.4 11.4 -11.5 14.0 -12.3 14.1 -11.7 15.9 -11.5 12.6 -13.0 13.2
Triglyceride (mg/dL) 6.4 38.5 7.8 39.7 7.1 41.5 5.4 28.3 10.1 37.4 -4.4† 41.1 5.3 39.8 11.4 35.5 9.9 46.9 4.2 33.4 7.8 32.4
Glucose (mg/dL) -0.8 5.4 0.6 4.6 -0.6 5.4 -0.3 5.0 -0.7 5.1 -0.1 6.2 -0.8 5.0 -0.2 5.9 -0.8 4.1 -0.4 6.1 -0.3 4.8
Insulin (uU/mL) 0.7 4.6 -0.4 3.4 0.7 4.7 -0.1 3.4 0.3 4.0 1.4 5.9 0.2 4.4 1.1 4.5 0.7 3.1 0.5 4.9 -0.4 5.5
SBP (mm Hg) -0.4 7.1 -2.4 7.2 -0.9 7.1 -0.3 7.4 -0.9 7.8 0.1 5.5 -1.1 7.9 0.4 6.1 0.8 7.8 -1.5 7.1 -0.5 7.5
DBP (mm Hg) -0.9 4.5 -2.4 4.4 -1.2 4.6 -1.2 4.2 -1.2 4.6 -1.4 4.1 -1.5 4.5 -0.6 4.4 -0.4 4.2 -1.6 5.1 -1.5 3.0
BAFMD (%) 1.5 3.0 0.2 2.7 1.1 3.0 2.1 3.0 1.4 3.1 0.9 2.9 1.4 3.0 1.2 3.1 1.3 3.4 1.3 2.8 1.3 2.8
†Significantly (p < 0.05) different from more common genetic variant
27aa/27aa 24aa/27aa





























Table 4.8 Genetic Frequencies by Cluster 
 
 
% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
Cluster 1 81.4 48 18.6 11 76.3 45 23.7 14 81.7 49 18.3 11 58.3 35 41.7 25 36.7 22 51.7 31 11.7 7
Cluster 2 85.7 18 14.3 3 71.4 15 28.6 6 75.0 15 25.0 5 55.0 11 45.0 9 52.4 11 38.1 8 9.5 2
Cluster 3 86.5 32 13.5 5 70.3 26 29.7 11 81.1 30 18.9 7 70.3 26 29.7 11 29.7 11 56.8 21 13.5 5
Cluster 4 88.2 30 11.8 4 79.4 27 20.6 7 88.2 30 11.8 4 64.7 22 35.3 12 41.2 14 41.2 14 17.6 6
Cluster 5 92.3 12 7.7 1 69.2 9 30.8 4 84.6 11 15.4 2 76.9 10 23.1 3 23.1 3 61.5 8 15.4 2
Cluster 6 94.6 35 5.4 2 75.7 28 24.3 9 86.5 32 13.5 5 73.0 27 27.0 10 45.9 17 37.8 14 16.2 6
Arg/Arg 24aa/24aa24aa/27aa27aa/27aaSer/*Thr/ThrHis/*Gln/GlnArg/*Cys/CysCys/*
Apo A-IV (Gln360→His) Apo B Signal Peptide (27aa→24aa)Apo A-IV (Thr347→Ser)Apo E (Arg158→Cys) Apo E (Cys112→Arg)
(n)
Variable Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
TC (m
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were maintained throughout the study. Additionally, it is important to note that the control group 
also had a modest decrease in caloric intake, but without significant changes in dietary fat, 
saturated fat, or cholesterol intake.  These findings are similar to other studies whose goals were 
to achieve a total fat intake of 15% of calories but on average achieved a total fat intake of 21-
23% of calories (Henderson et al. 1990; Lee-Han et al. 1988).  
It is also noted that the average caloric intake for both groups at baseline was already at 
approximately 1800 kcal which is below the recommended caloric intake for men and only 200 
kcal above the recommended intake for even sedentary individuals (U.S. Department of Health 
and Human Services and U.S. Department of Agriculture, 2005). Thus further dietary 
adjustments were arguably difficult to achieve. The unique contribution of the present study is 
that it focused on middle-aged, asymptomatic men and women with normal cholesterol levels, in 
comparison to at-risk women (The Women’s Health Trial Vanguard Study (Henderson et al. 
1990)), women with a history of breast cancer (The Breast Dysplasia Intervention Trial (Lee-Han 
et al. 1988)), the Women’s Nutrition Program (Heber et al. 1992), the Dietary Alternatives Study 
(Walden et al. 1991) and studies in hyperlipidemic individuals (Brown et al.1984; Thuesen et 
al.1986). 
4.4.2 Impact of Dietary Intervention on Biochemical, Body Weight, Body Fat and Vascular 
Markers  
The present findings indicate that long-term changes in dietary fat, saturated fat, and 
cholesterol intake in middle-aged men and women with normal lipid levels produced modest but 
significant mean decreases in TC and LDL-C. Adversely, there was an initial significant 
decrease in HDL-C, an analyte considered to be cardioprotective (Castelli et al.1986; Gordon et 
al. 1977), of 5.5% at month 3 in the diet intervention group. However, HDL-C levels gradually 
rebounded, such that the mean HDL-C levels for the intervention group was within 1.9% of the 
pre-intervention concentrations (p>0.05). The ability of the HDL-C to rebound is an important 
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finding, as there are several studies that suggest that low fat diets in fact may increase 
cardiovascular risk secondary to a reduction in the cardioprotective lipid (Beynen et al. 1987; 
Katan et al. 1986).  It is interesting to consider what mechanisms may have contributed to the 
rebound affect of the HDL-C, considering that TC and LDL-C remained significantly lower 
across the trial. Several mechanisms could have contributed which include a change in dietary 
habits, such as the use of certain plant oils, nuts, marine foods or other dietary modifications 
known to elevate HDL-C levels (National Cholesterol Education Program 2001). Likewise, a 
change in HDL-C is also noted in individuals whose daily activity patterns change (National 
Cholesterol Education Program 2001). 
Although modest, the observed changes in lipid status, in the current study, are 
comparable with the findings of other low-fat dietary interventions (Nordman et al. 2006; Foster 
et al. 2003; Samaha et al. 2003; Stern et al. 2004; Yancy et al. 2004; Dansinger et al. 2005) 
which have, on average, shown a -1.5 mg/dL change in HDL-C (Nordman et al. 2006).  Related 
to these adverse changes, there are many that advocate other dietary interventions such as those 
which incorporate soy protein, soluble fiber, soy lecithin, and plant sterols (Nicholosi et al. 
2001).  Those dietary interventions are aimed at lowering LDL-C without decreasing the HDL-C 
level. Non-dietary interventions, such as statin therapy, have been associated with regression of 
coronary atherosclerosis only in situations where the LDL-C is dramatically lowered (to < 87.5 
mg/dL), HDL-C is increased by more than 7.5%, and LDL-C/HDL-C decreases by 26% 
(Nicholas et al. 2007). When those findings are compared to the current study’s findings of a 
decrease in LDL-C to 124 mg/dL, an adverse decrease in HDL-C, and only a 7.6% decrease in 
LDL/HDL-C, the current study’s data questions the global effectiveness of  the dietary 
intervention strategy employed in this study. The changes seen the individual lipid analytes, TC, 
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LDL-C, HDL-C in this study, although significant, were minimal compared to the levels seen 
following non-dietary changes. 
Despite the reduction in TC and LDL-C, lipid balance was minimally affected across the 
trial. In fact, the TC/HDL-C ratio across the trial was not different from the control group despite 
a final decrease of 0.14 mg/dL for the intervention group, as compared to 0.04 mg/dL in controls.  
In contrast, the change in LDL-C/HDL-C ratio was statistically different between groups, 
However, both lipid ratios, remained in the average risk category (Tietz, 1995). It is of course 
recognized that lipid ratios are considered to be better predicators of cardiovascular risk than the 
individual lipid components (Nicholls et al. 2007; Kinosian et al. 1994; Nam et al. 2006; 
Stampfer et al. 1991; Ridker et al. 2001).  Thus, a reduction in lipid ratios should always be 
considered an important finding.  
Interestingly, data in the present study revealed an increase in BAFMD, a commonly 
used biomarker of systemic vascular “health,” and a decrease in brachial artery diameter in both 
the diet-intervention and the control groups despite clear differences in dietary fat, saturated fat, 
and cholesterol intake. The fact that both groups changed is somewhat perplexing and, upon first 
glance, it does not appear to be attributable to any dietary changes. Thus, one must conclude that 
the observed changes were apparently not related to the low fat diet intervention. 
However, it is interesting that both groups revealed a significant increase in 
vasoreactivity at month 3. Thus it is important to at least speculate how vasoreactivity could have 
changed in both groups, assuming the change is indeed real. It is believed such a discussion may 
contribute to the development of future studies involving these issues.  
It is speculated that the observed changes in vasoreactivity at the 3 month mark, in both 
groups, could be a reflection of an alteration in the endothelial milieu, in favor of greater 
reactivity. An alteration in the endothelial milieu could be a consequence of changes in 
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vasomotor tone; small changes in a number of diet related factors, rather than any one factor 
specifically; non-dietary related changes; and hidden factors not part of the battery of end points 
selected. Each of these areas will be discussed briefly.  
Changes in vasomotor tone, generally, are related to changes in autonomic balance. 
Specifically, an increase in sympathetic activity typically is associated with less reactivity and a 
slight increase in vessel diameter (Hijmering et al. 2002; Lind et al. 2002; Spieker et al. 2002). 
Thus if the participants in this study had any sort of anticipatory or hyperadrenergic response to 
the initial testing environment, it would not be completely out of the question that on subsequent 
tests the participants could have been more relaxed. This sort of Hawthorne effect is in fact a 
common occurrence in many clinical studies and must always be considered in the interpretation 
of the data (McCarney et al. 2007). Interestingly, the findings in the current study do support a 
small but not statistically significant change in diastolic blood pressure from baseline to month 3 
in both groups. However, lack of more definitive evidence about autonomic balance prevents a 
more confident statement about this issue. 
A change in the endothelial milieu could also be a consequence of small and statistically 
non-significant changes in a large number of dietary factors. For example, a reduction in daily 
caloric intake, LDL-C, TC/HDL-C, and LDL-C/HDL-C ratios were noted in both groups at the 3 
month mark. In addition, whereas the intervention group had a reduction in HDL-C and increase 
in triglycerides at month 3, the opposite was seen in the control group. Arguably the power of 
many is always greater than that of few. So a small change in a number of factors may have 
contributed to a more favorable environment that could have led to increased vasoreactivity. It is 
important to recognize that this explanation may fit the initial changes observed at 3 months, but 
it is difficult to rationalize that this also explains why vasoreactivity remained elevated for both 
groups throughout the trial.   
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A change in the endothelial milieu could also be a consequence of non-dietary related 
changes. It is important to understand that the majority of participants entered the study with the 
anticipation of making certain adjustments to their lives that they felt were in their best interest. 
Having been randomized to a control group may not have “prevented” individuals from making 
certain changes. An obvious change that could have been made was a change in physical activity 
levels. This was unfortunately poorly assessed in this study, and in fact was not considered a 
major end-point. It is, therefore, intriguing to restate that individuals with the greatest fat loss 
over the course of the study also had the greatest improvement in vasoreactivity, but only if their 
vasoreactivity was in the lower two tertiles at the beginning of the study. Perhaps more 
interestingly, this finding was only observed in men. These findings are similar to other studies 
that have shown that decreases in weight and BMI are correlated with improved vascular 
reactivity (Hamdy et al. 2003; Caballero et al. 1999; Shechter et al. 2006).  This same association 
was seen between the on-trial changes in BAFMD and the reported caloric intake.  This finding 
that subpopulations of individuals, particularly those with poor vascular reactivity initially, 
respond more favorably to intervention is similar to the findings seen related to exercise 
intervention and vascular reactivity. Perhaps the approach should be to provide people with 
normal vascular function with a diet that focuses on calorie reduction, whereas those with 
reduced vasoreactivity may need calorie reduction plus saturated fat reduction and increase in 
monounsaturated fats. 
Finally, given the complexity of vascular control, there are many other factors that could 
have contributed to a change in vasoreactivity. The focus of this trial was certainly toward lipids, 
and so many hidden factors could have changed that were not measured in this trial. In addition, 
it is possible that the inability to relate changes observed in BAFMD to dietary changes is 
masked by the complexity of individual responses to dietary changes.  It is likely that a multitude 
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of both genetic and biochemical responses involved in lipid metabolism and vascular health may 
be triggered by a modification of the intake of total fat, saturated fat, and cholesterol, with a large 
range of variable responses.  
It is also important to reflect on the lack of robustness of the change in vasoreactivity. In 
other words if it is assumed that the change in vasoreactivity is not due to any dietary 
intervention can this be explained. Interestingly, recent studies suggest that exercise training 
may, in fact, be an effective signal that contributes to actual changes within the endothelial cell 
(Chapter 3). Although the mechanism is not entirely known, the contraction-relaxation cycle 
associated with muscular work is believed to alter the shear stress on the endothelial wall 
(Laughlin 1995). In fact, it appears that intermittent changes in shear stress serve as a major 
signal for vascular adaptations. Studies show that exercise training results in rapid improvements 
in endothelial function, believed in part due to an increase in nitric oxide synthase (Laughlin et 
al. 2003), secondary to changes in the mRNA for the enzyme (Egger et al. 1997a; Wang et al. 
1993; Woodman et al. 1999; Laughlin et al. 2003). It is thought that this leads to an increase in 
vessel diameter, structural modifications within the vessel wall, and eventual return of the pre-
training endothelial response to the new settings (Laughlin 1995). It is possible that low-fat diet 
interventions do not provide a sufficient stimulus to the vascular system. Thus it is perhaps not 
surprising that there are virtually no long-term diet trials which have reported favorable changes 
in BAFMD.  Future studies which combine diet- and exercise interventions in middle-aged men 
and women may consequently have a much greater impact on vascular biology, and importantly 
atherosclerotic risk, by altering both the external and internal endothelial environment. 
4.4.3 Clustering of Responses to Dietary Intervention 
So as suggested in the previous section, changes in biochemical lipid levels and other 
vascular risk factors to a low fat dietary intervention are likely to be influenced by multiple 
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factors, and may not be clearly visible in any one independent risk marker or consistent from 
individual to individual.  This is evidenced by the large variability in individual responses in 
those exposed to a low-fat diet, with some individuals showing small changes to others showing 
markedly potentially adverse changes (Katan and Beyen 1987; Schaefer et al.1997; Masson et al. 
2003).   
To more thoroughly explore the classification of participants by their individual 
responses rather than by the group mean, the present study used a cluster analysis to identify any 
cluster of variables that may have responded to the diet in a more predictable manner.  Six non-
overlapping groups (clusters) with patterns of similar biochemical and vascular responses and 
potentially more meaningful groups were identified.  These groups showed that there was a 
range of changes in lipid and biochemical responses, with differences of total cholesterol 
changes ranging from -26 mg/dL to 3 mg/dL.  Clusters 1 and 3 consisted predominantly of the 
control group (76% of controls); however, 45 diet-intervention participants (31%) were grouped 
in Clusters 1 and 3, which yielded virtually no changes in serum lipids, thus illustrating either the 
lack of effectiveness of low-fat dietary intervention on some individuals or the lack of 
compliance of a large portion of diet-intervention participants.  Twenty-five percent of the 
control participants grouped into three clusters, Clusters 4, 5 and 6, which had large changes in 
serum lipids despite no self-reported changes in dietary intake of fat and cholesterol. On the 
other hand, 56% of the diet intervention group was classified into Clusters 2, 4, and 6, all clusters 
with significant changes in serum lipids (Figure 4.4).  These clusters had decreases in total 
cholesterol and LDL-cholesterol; however, only Cluster 2, encompassing 14 diet-intervention 
and 7 control participants, did not have a decrease in HDL-C.  It has been shown that low fat 
diets reduce cardiovascular risk but have the adverse effect of also lowering HDL-C (Nicolosi et 
al. 2001). Interestingly, however, is the fact that Cluster 2’s most substantial dietary change 
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seems to be the alteration in intake of calories with mean decrease of 560 kcal over the study, 
once again emphasizing the beneficial changes that occurred with a decrease in caloric intake.  
Data from this study show that 50% of the clusters responded to low fat dietary intervention with 
decreases in HDL-C.  Interestingly, the majority of the participants in the dietary-intervention 
group had substantial decreases in TC but many of these had increases in triglycerides as 
described by other low fat dietary studies. Only Cluster 2 showed a decrease (-8.0%) in the 
TC/HDL-C ratio that was significantly different from all other clusters.  Clusters 2 and 4 had 
significant decreases (-7.06% and -10.25%, respectively) in LDL-C/HDL-C ratio. Those 
individuals in the low fat diet group did show substantial decreases in BMI with many having an 
increase in insulin.  Clusters 3, 4, and 5 did have significant decreases in glucose similar to the 
diet-intervention versus control findings.  There were virtually no changes in DBP or SBP 
overtime or between groups.   
Despite obvious clustering of similarly responding biochemical changes, there were no 
groups with significant differences in vascular reactivity as measured by BAFMD. This suggests 
that dietary changes may not effectively alter endothelial function.  In fact, cluster 3, the group 
showing virtually no lipid or other biochemical changes had the greatest increase in 
vasoreactivity. These finding contradict the suggestions by Raitakari et al. (2005) that long term, 
low-fat diets may increase vascular reactivity.  Acute doses of high fat meals have been shown to 
decrease BAFMD (Cortes et al. 2006; Tushuizeri et al. 2006; Ng et al. 2001); however, chronic 
reduction in fat levels may not significantly alter the environment surrounding the endothelium 
to sufficiently result in improvements of vascular function.  It is possible that the inconsistency 
of results on dietary intervention producing detectable changes in BAFMD is due to the lack of 
an adequate in vivo direct stimulus to the vasculature. 
Cluster analysis did reveal that there was variability in serum lipid responses to a low-fat 
dietary intervention.  Cluster analysis was a vital tool which assisted in deconvoluting the 
complex response that results with interventions aimed to evaluate such a multifaceted disease as 
cardiovascular disease. More studies are needed to identify baseline characteristics of those 
individuals that do show favorable lipid responses.  Additional studies may lead to the 
acceptance that a diversity of interventions based on one’s pre-trial characteristics is the 
appropriate prescription to decrease one’s cardiovascular risk. 
4.4.4 Role of Genetic Polymorphisms 
There is evidence that the variability of lipid and lipoprotein responses to dietary 
interventions designed to lower total and saturated fat may be due to differences in genes such as 
apolipoprotein A-IV, apolipoprotein B, and apolipoprotein E (Masson et al. 2003; Dreon and 
Kraus 1997; Ordovas and Galluzzi 1999; Schaefer et al. 1997). Apolipoprotein E is present in 
several plasma lipoproteins of importance in lipid metabolism.  The presence of Apo E (Cys112 
→ Arg), apo E4, has been associated with a greater reduction in LDL-C and significantly smaller 
reductions in HDL-C during low fat dietary interventions (Hagberg et al. 2000). Additionally, in 
Type 2 diabetics, the apolipoprotein E4 allele has been shown to be associated with a decrease in 
BAFMD during the early stages of diabetes (Guangda et al. 2003, 2006) but also results in 
greater reductions in LDL-C with diet therapy (Saito et al. 2004), thus suggesting that carriers of 
the apolipoprotein E4 allele might benefit most from dietary reductions in total fat and saturated 
fat. The apolipoprotein E (Arg158 Cys), apo E2, has been shown to be associated with reduced 
responsiveness to low fat diets (Hagberg et al. 2000; Kesaniemi et al. 1986; Dreon et al. 1995). 
On the other hand, there is evidence that apolipoprotein E2 allele is associated with more 
responsiveness to statin therapy showing a greater reduction in TC and LDL-C as compared to 
apolipoprotein E4 individuals (Hagberg et al. 2000). Evaluation of all diet-intervention 
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participants in the current study showed no effect of either the apolipoprotein E2 or 
apolipoprotein E4 allele on serum lipids or vascular risk factors in response to a low-fat dietary 
intervention.  However, cluster analysis revealed that Cluster 1 had the highest frequency of 
apolipoprotein E2, typically associated with a decreased responsiveness to low fat diets, and 
consisted of a large amount of diet-intervention participants with virtually no changes in serum 
lipids other than a modest increase in HDL-C. On the other hand, Cluster 5 had the highest 
frequency of apolipoprotein E4 allele but only had minor changes (-3.7%) in LDL-C. 
In contrast to the potential positive effect of the apolipoprotein E4 allele, individuals 
possessing one or two copies of the apolipoprotein A-IV (Gln360 His) polymorphism have been 
shown to respond to low-fat dietary interventions with a greater decrease in HDL-C (Jansen et al. 
1997).  These findings suggest that individuals with even a single copy of the apolipoprotein A-
IV (His360) may be adversely affected by a low-fat dietary intervention.  However, the current 
study failed to show a greater decrease in HDL-C in those individuals with at least one copy of 
apolipoprotein A-IV (His360).  The only significant finding was a statistically significant 
decrease in triglycerides.  Likewise, there was no finding in the cluster analysis that indicated a 
decrease in HDL-C in the clusters with the highest frequency of the apolipoprotein A-IV 
(His360).  In contrast to the potential negative effects of the apolipoprotein A-IV (His360), 
individuals with the apolipoprotein A-IV (Thr347 Ser) allele have been shown to have a greater 
decrease in LDL-C in response to low-fat dietary intervention (Ordovas et al. 1995).  
Additionally, another study found that carriers of the (Ser347) allele responded to a decrease in 
dietary fat with a greater decrease in total cholesterol, LDL-C, and apolipoprotein B (Jansen et 
al. 1997).  However, the current study was not able to detect the same findings.   
Individuals who are homozygous for the deletion polymorphism in the Apo B signal 
peptide (27aa 24aa) have been shown to have greater decreases in HDL-C on low-fat dietary 
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interventions in controlled feeding studies (unpublished data from Pennington Biomedical 
Research Cener, DAIRY study).  The effect of apolipoprotein B signal peptide polymorphism on 
HDL-C was replicated in this study only when the most dietary compliant participants were 
evaluated (data not shown).   Those participants who were homozygous for the shorter 24 amino 
acid length signal peptide experienced the greatest declines in HDL-C.  Additionally, Clusters 4 
and 6 possessed the highest frequency of the homozygous deletion (17% and 16%, respectively).  
Clusters 4 and 6, each with six participants, had the greatest decrease in HDL-C of all cluster 
groups (-8% and -9%, respectively).  These findings potentially indicate that individuals, who are 
homozygous for the deletion mutation in the apolipoprotein B signal peptide, may be adversely 
affected by dietary modifications which decrease the amount of dietary fat.   
The finding that specific genotypes may alter one’s response to low-fat dietary 
interventions, questions the global effectiveness of such diets for all individuals.  More thorough 
investigation of the genetic influence of biochemical and vascular responses to dietary and other 
forms of interventions are needed.  Studies designed to either prescreen for genotype selection or 
power appropriately for genetic frequencies are needed to allow for adequate testing of 
genetically linked responses to cardiovascular risk intervention studies.  Such studies will lead to 
the design of intervention programs tailored to both the positive and negative genetic influence. 
4.4.5 Value of Dietary Modification of Cardiovascular Risk factors in Middle Aged Men and 
Women 
These data do not support the use of a low fat dietary intervention to decrease 
cardiovascular risk factors, particularly vascular reactivity in “healthy” individuals between 45 to 
65 years old. In fact the results indicate very modest biochemical changes for a great deal of 
effort. Most notably is the fact that there are large variabilities in responses to a global 
application of a low fat diet for all individuals.  Importantly, greater than 80% of those 
individuals in the low fat diet group had a decrease in HDL-C, with “clusters” of individuals 
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experiencing as much as a 15% decrease in HDL-C.  The low fat diet and resulting biochemical 
changes could not be associated with any changes in the vasculature in these individuals.  The 
only changes in vascular “health” were related to changes in body fat and caloric intake.  These 
findings highlight the importance of a multifactorial effort in ensuring that cardiovascular risk 
factors are controlled. In terms of behavior it must include both a change in energy intake as well 
as expenditure. The benefits of increasing expenditure, via physical activity, on cardiovascular 
risk factors are significant. As shown in Chapter 3, evidence is overwhelming that physical 
activity improves vascular “health.”  Therefore, the current findings show that low fat dietary 
modifications alone are inadequate in “healthy” 45 to 65 year old adults in altering one’s 
cardiovascular risk unless energy expenditure is incorporated. 
4.4.6 Limitations 
Despite the results indicating that participants in the diet-intervention group achieved 
significant reductions in total fat intake, the nutrient targets were not met, indicating that the 
participants found it more difficult or unacceptable to decrease intake of foods containing 
saturated fat and cholesterol. Additionally, the study lacked data on participants’ physical 
activity, a potential confounding factor to both changes in serum lipids and vascular reactivity.   
The lack of agreement between previously published observations regarding the selected 
polymorphisms and the observations in the current study may be related to the fact that most 
studies with significant gene-diet interactions have been found in highly controlled dietary 
intervention studies in which participants are provided with the foods.  This level of dietary 
control may have allowed for greater detection of effects of genetic polymorphisms on lipid and 
vascular responses.   
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4.5 Conclusion 
This study indicates that middle-aged men and women instructed to consume a low-fat 
diet, reported, within 3 months, significant reductions in total fat, saturated fat, and cholesterol 
intake, which corresponded with a moderate, yet, significant change in LDL cholesterol, without 
significant relapse over the remaining 9 months. However, despite a reduction in LDL 
cholesterol, the diet intervention appeared to have only a modest effect on lipid balance as 
indicated by small reductions in the TC/HDL and LDL/HDL ratios. Additionally, a clustering of 
lipid and vascular responses were seen indicating the array of responses that groups of 
individuals have in response to dietary interventions.  Gene-diet interaction evaluation did reveal 
that genetic polymorphisms, such as the deletion at the apolipoprotein B signal peptide (24 
amino acid) may be associated with varying responses to low-fat dietary interventions.  
Interestingly, the data suggest that despite self-reported reductions in total fat, saturated fat, and 
cholesterol intake, markers of vascular “health” were not significantly changed in this 
population. However, individuals’ brachial artery reactivity increased by 3 months in both 






This final chapter serves as a summary of the findings of this body of work, the 
knowledge gained, and suggestions for potential future studies.  As a licensed Clinical 
Laboratory Scientist with experience in genetic testing, my goal has been to merge my interests 
in molecular biology, physiology, biochemistry, functionality and relationships with disease and 
interventions. The three projects described in this dissertation have integrated these aspects in the 
study of the relationship of brachial artery flow mediated dilation and vascular function. 
Cardiovascular disease is the leading cause of death in the United States, and Louisiana 
ranks as one of the highest of the states for mortality from it.  There are approximately 80.7 
million American adults with some form of cardiovascular disease, and cardiovascular disease 
accounted for 36.3% of all deaths in the United States in 2004.  Since the 1970’s there has been a 
484% increase in cardiovascular related operations and procedures.  With the high prevalence of 
this disease, there is a large economic impact on society.  It is estimated that the cost of treating 
cardiovascular disease in the United States for 2008 will be $448.5 billion (American Heart 
Association, 2008).  
The development of atherosclerosis is a long and complex process.   It is theorized that 
repeated challenges to the endothelial lining of the vascular system weaken and eventually break 
down the lining.  This leaves the vessel vulnerable to factors known to contribute to the 
formation of lesions and plaques. Because of the hypothesis that a breakdown in the vascular 
endothelial lining precedes atherogenesis, development of biomarkers and tests for vascular 
endothelial function have emerged. BAFMD is a test of endothelial function which is theorized 
to measure the degree and severity of CVD (Corretti et al. 1995).   Assessment of BAFMD is 
 79
related to structural changes of the carotid arteries (Ravikumar et al. 2002), coronary artery 
reactivity (Anderson et al. 1995; Takase et al. 1998), coronary stenosis (Kaku et al. 1998), and 
the extent and severity of coronary artery disease (Neunteufl et al. 1997). Additionally, impaired 
BAFMD has been shown to independently predict long-term cardiovascular events in patients 
with peripheral artery disease (Gokce et al. 2003).  Likewise, when evaluating patients with 
coronary artery disease, BAFMD has been shown to be an independent prognostic measurement 
(Bae et al. 2004. Neunteufl et al. 2000; Gokce et al. 2002; Brevetti  et al. 2003; Perticone et al. 
2001; Modena et al. 2002; Fathi et al. 2004) which is correlated to coronary events (Chan et al. 
2003).  
In this project we show that there is a relationship between biochemical analytes and 
vascular reactivity, specifically homocysteine to BAFMD.  But additionally we show that there 
is a correlation of the MTHFR genotype, independent of homocysteine levels, and vascular 
reactivity, thus emphasizing the potential impact of genetic variations on vascular “health.”  In 
exploration of the ability to prevent vascular disease or alter one’s vascular “health,” this work 
showed that indeed vasoreactivity was modifiable, at least through the modality of physical 
activity. Additionally, it was noted that there was variability in the change in vasoreactivity and 
this change was dependent on several factors.  It was found that larger changes in BAFMD were 
seen in at risk or diseased subjects compared to healthy subjects, shorter duration studies (< to 8 
weeks) had a larger mean effect size than did longer duration studies (> 8 weeks), and aerobic 
training has the largest effect on BAFMD.  Once again these findings reveal the spectrum of 
responses when different interventions are utilized. 
Finally, knowing that there are both biochemical and genetic links that contribute to the 
“health” of the vasculature and that vascular function is modifiable, at least with exercise 
training, it was then plausible to question the effects of other often prescribed intervention 
 80
programs aimed at prevention of cardiovascular disease.  One such method is dietary 
intervention aimed at decreasing one’s cardiovascular risk by adopting a global approach which 
decreases the intake of dietary fat. The final study did reveal that middle-aged men and women 
instructed to consume a low-fat diet, reported, within 3 months, significant reductions in total fat, 
saturated fat, and cholesterol intake, which corresponded with a moderate, yet, significant change 
in LDL cholesterol, without significant relapse over the remaining 9 months. However, despite a 
reduction in LDL cholesterol and great efforts to decrease dietary fat intake, the diet intervention 
resulted in a decrease in HDL-C, a cardioprotective analyte, and appeared to have only a modest 
effect on lipid balance as indicated by small reductions in the TC/HDL and LDL/HDL ratios.  
Additionally, the only association to changes in vascular reactivity was seen in participants who 
had “low” or “no” vascular reactivity prior to the start of the trial and had large changes in 
percent body fat or caloric intake.  To better appreciate the complexity of responses that occurs 
with an intervention program, a clustering of lipid and vascular responses were evaluated.  This 
technique indeed showed that there was a vast array of responses to dietary intervention with 
only a small portion of the participants’ lipid status responding favorably and no correlation 
between changes in dietary fat intake and vasoreactivity.  Although the final study was not 
designed specifically to test gene-diet interaction, evaluation did reveal that genetic 
polymorphisms, such as the deletion at the apolipoprotein B signal peptide (24 amino acid) may 
be associated with varying responses to low-fat dietary interventions. This, once again, 
emphasizes the variability in responses to a low fat diet and the lack of direct effect on vascular 
“health.” 
Booth et al. (2000) suggest that there has been an epidemic of chronic diseases which 
include cardiovascular disease.  They argue that reducing the incidence of these diseases will 
require a more non-traditional approach, such as primary prevention instead of treatment after 
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the development of disease.  To truly combat against cardiovascular disease and focus on 
prevention, we must continue to pursue information regarding the core causes of these diseases 
and the multiple factors that contribute to the development and prevention of such disease.   
Consequently, intervention programs must be customized to the individual and accept the idea 
that “one size does not fit all.”  Because many diseases, such as cardiovascular disease, are 
related to both environmental and genetic interactions, it is important to appreciate the possibility 
that a global population intervention may not provide the most effective results to all individuals.   
As shown in this body of work there are a multitude of biochemical and genetic factors that 
affect vascular “health” and responses to intervention programs and indeed there is large 
variability in responses between individuals to the same intervention.  Genetic polymorphisms 
are most likely a predominant contributor to such variability and as such it is feasible begin to 
focus research on genetically driven intervention programs. As illustrated in Figure 5.1, genetic 
polymorphisms in genes involved in normal vascular function result in phenotypic variations 
which alter key mechanisms such as enzymatic efficiencies and protein morphology.  Such 
variations result in alterations of biochemical concentrations of analytes such as nitric oxide, 
prostaglandins, and other substrates/cofactors needed for biochemical reactions.  These 
alterations result in variations in the balance of critically regulated systems such as coagulation, 
inflammation and cell proliferation.  Alterations in these processes ultimately result in alterations 
in vascular biology and endothelial function which may be measured through tools such as 
BAFMD.  For example, Guangda, et al., found that individuals who possess the apolipoprotein 
E4 allele have a decreased BAFMD (Guangda et al. 2003, 2006). This illustrates the idea that 
perhaps individuals with the E4 allele may benefit more from an aerobic-based intervention, an 















Genetically Driven Intervention Approach
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Figure 5.1 Genetically Driven Intervention Approach (NOS = nitric oxide synthase; 
ACE=angiotension converting enzyme; apoE4=apolipoprotein E4 genotype; 
MTHFR=methylenetetrahydrofolate reductase) 
 
shown that since individuals with the deletion polymorphism at the apolipoprotein B signal 
peptide are more likely to experience greater decreases in HDL-C levels when exposed to a low-
fat diet (unpublished data from Pennington Biomedical Research Cener, DAIRY study; and 
Chapter 4), these individuals would benefit more from modified dietary interventions such as 
those which incorporate soy protein, soluble fiber, soy lecithin, and plant sterols (Nicholosi et al. 
2001) or high intensity exercise to counter- balance this genetically based response. Because of 
this genetic influence, future studies should be designed to evaluate genetic polymorphisms as 
they relate to vascular function.  It is likely that due to genetic variability all individuals do not 
respond the same to a given intervention.  Additionally, different modalities, such as dietary 
alteration, changes in physical activity, or the administration of pharmacological agents result in 
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varying effectiveness which may possibly be linked to genetic variants.  Likewise, interventions 
will likely need to be tailored to the individual based on such genotypical variations and 
responsiveness to certain factors in order to maximize the effectiveness of decreasing disease 
progression and ultimately preventing disease.  
In summary, this work indicated positive relationships between vasoreactivity and some 
biochemical risk factors for cardiovascular disease and well as the role that genetic variations 
affect the responses to interventions designed to prevent or decrease the risk of cardiovascular 
disease. As of date, there are less than fifty studies that have evaluated the relationship between 
genetic variation and BAFMD, with the majority of these focused on only a few genes such as 
nitric oxide synthase and angiotensin converting enzyme. These results promote future studies 
which will explore an increased understanding of individual responses to interventions and the 
genetic influences on these responses, thus making it possible to potentially provide a modified 














Allen JD, Geaghan JP, Greenway F, Welsch MA. Time course of improved flow-mediated 
dilation after short-term exercise training. Med Sci Sports Exerc. 2003 May;35(5):847-53.  
 
American Heart Association. Heart Disease and Stroke Statistics – Our Guide to Current 
Statistics and the Supplement to our Heart and Stroke Facts - 2008 Update, Dallas, Texas: 
American Heart Association; 2008. 
  
American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, 
Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, 
Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and 
lifestyle recommendations revision 2006: a scientific statement from the American Heart 
Association Nutrition Committee. Circulation. 2006 Jul 4;114(1):82-96. Epub 2006 Jun 19. 
Erratum in: Circulation. 2006 Dec 5;114(23):e629. Circulation. 2006 Jul 4;114(1):e27.  
 
Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, 
Ganz P, Creager MA, Yeung AC, et al. Close relation of endothelial function in the human 
coronary and peripheral circulations. J Am Coll Cardiol. 1995 Nov 1;26(5):1235-41. 
 
Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in 
humans. Circulation. 1989 Jan;79(1):93-100. 
 
Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total 
homocysteine and coronary heart disease. Int J Epidemiol. 1995 Aug;24(4):704-9. 
 
Asztalos B, Lefevre M, Wong L, Foster TA, Tulley R, Windhauser M, Zhang W, Roheim 
PS. Differential response to low-fat diet between low and normal HDL-cholesterol subjects. J 
Lipid Res. 2000 Mar;41(3):321-8. 
 
Bae JH, Bassenge E, Kim MH, Park KR, Kim KY, Synn YC, Schwemmer M. Impact of left 
ventricular ejection fraction on endothelial function in patients with coronary artery 
disease.Clin Cardiol. 2004 Jun;27(6):333-7.  
 
Barnard RJ. Effects of life-style modification on serum lipids.Arch Intern Med. 1991 
Jul;151(7):1389-94. 
 
Belardinelli R, Lacalaprice F, Faccenda E, Purcaro A, Perna G. Effects of short-term 
moderate exercise training on sexual function in male patients with chronic stable heart 
failure. Int J Cardiol. 2005 May 11;101(1):83-90.  
 
Beynen AC, Katan MB, Van Zutphen LF. Hypo- and hyperresponders: individual differences 
in the response of serum cholesterol concentration to changes in diet. Adv Lipid Res. 
1987;22:115-71. 
 
Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Waugh R, Georgiades A, Bacon SL, 
Hayano J, Coleman RE, Hinderliter A. Effects of exercise and stress management training on 
 85
markers of cardiovascular risk in patients with ischemic heart disease: a randomized 
controlled trial. JAMA. 2005 Apr 6;293(13):1626-34.  
 
Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, 
Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral 
occlusive arterial disease. N Engl J Med. 1985 Sep 19;313(12):709-15. 
 
Booth FW, Gordon SE, Carlson CJ, Hamilton MT. Waging war on modern chronic diseases: 
primary prevention through exercise biology. J Appl Physiol. 2000 Feb;88(2):774-87. 
 
Brendle DC, Joseph LJ, Corretti MC, Gardner AW, Katzel LI. Effects of exercise 
rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J 
Cardiol. 2001 Feb 1;87(3):324-9.  
 
Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, Scopacasa F. 
Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers 
of inflammation and severity of peripheral circulatory impairment but not to classic risk 
factors and atherosclerotic burden. J Vasc Surg. 2003 Aug;38(2):374-9.  
 
Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, Luepker R, Mittleman M, 
Samet J, Smith SC Jr, Tager I; Expert Panel on Population and Prevention Science of the 
American Heart Association. Air pollution and cardiovascular disease: a statement for 
healthcare professionals from the Expert Panel on Population and Prevention Science of the 
American Heart Association. Circulation. 2004 Jun 1;109(21):2655-71.  
 
Brown GD, Whyte L, Gee MI, Crockford PM, Grace M, Oberle K, Williams HT, Hutchison 
KJ. Effects of two "lipid-lowering" diets on plasma lipid levels of patients with peripheral 
vascular disease. J Am Diet Assoc. 1984 May;84(5):546-50. 
 
Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, 
Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at 
risk for type 2 diabetes. Diabetes. 1999 Sep;48(9):1856-62. 
 
Carroll M, Sempos C, Briefel R, Gray S, Johnson C. Serum lipids of adults 20-74 years: 
United States, 1976-80. Vital Health Stat 11. 1993 Mar;(242):1-107.  
 
Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of 
coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 
1986 Nov 28;256(20):2835-8.  
 
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd 
JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at 
risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.  
 
 
Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic 
importance of endothelial dysfunction and carotid atheroma burden in patients with coronary 
artery disease. J Am Coll Cardiol. 2003 Sep 17;42(6):1037-43.  
 86
 
Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J Jr, 
Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene 
with plasma homocysteine in patients with premature coronary artery disease. Arterioscler 
Thromb Vasc Biol. 1997 Mar;17(3):569-73.  
 
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. 
Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 
Apr 25;324(17):1149-55.  
 
Clarkson P, Montgomery HE, Mullen MJ, Donald AE, Powe AJ, Bull T, Jubb M, World M, 
Deanfield JE. Exercise training enhances endothelial function in young men. J Am Coll 
Cardiol. 1999 Apr;33(5):1379-85.  
 
Cohen JA, Jeffers BW, Stabler S, Schrier RW, Estascio R. Increasing homocysteine levels 
and diabetic autonomic neuropathy. Auton Neurosci. 2001 Mar 23;87(2-3):268-73.  
 
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, 
Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; 
International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound 
assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a 
report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 
Jan 16;39(2):257-65. Erratum in: J Am Coll Cardiol 2002 Mar 20;39(6):1082. 
 
Corretti MC, Plotnick GD, Vogel RA. Technical aspects of evaluating brachial artery 
vasodilatation using high-frequency ultrasound. Am J Physiol. 1995 Apr;268(4 Pt 2):H1397-
404. 
 
Cortés B, Núñez I, Cofán M, Gilabert R, Pérez-Heras A, Casals E, Deulofeu R, Ros E. Acute 
effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial 
function. J Am Coll Cardiol. 2006 Oct 17;48(8):1666-71. Epub 2006 Sep 26. 
 
Cosentino F, Katusić ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide 
synthase in coronary arteries. Circulation. 1995 Jan 1;91(1):139-44. 
 
Crispino CC, Fernandes KG, Kamogawa MY, Nóbrega JA, Nogueira AR, Ferreira MM. 
Multivariate classification of cigarettes according to their elemental content determined by 
inductively coupled plasma optical emission spectrometry. Anal Sci. 2007 Apr;23(4):435-8.  
 
Crouse JR, Goldbourt U, Evans G, Pinsky J, Sharrett AR, Sorlie P, Riley W, Heiss G. 
Arterial enlargement in the atherosclerosis risk in communities (ARIC) cohort. In vivo 
quantification of carotid arterial enlargement. The ARIC Investigators. Stroke. 1994 
Jul;25(7):1354-9.  
 
Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, 
Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a 
randomized trial. JAMA. 2005 Jan 5;293(1):43-53.  
 
 87
de Bree A, Verschuren WM, Bjørke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, 
Blom HJ. Effect of the methylenetetrahydrofolate reductase 677C-->T mutation on the 
relations among folate intake and plasma folate and homocysteine concentrations in a general 
population sample. Am J Clin Nutr. 2003 Mar;77(3):687-93.  
 
de Franchis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, de Stefano V, Margaglione M, 
Mazzola G, di Minno G, Andria G. Elevated total plasma homocysteine and 677C-->T 
mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular 
disease. Am J Hum Genet. 1996 Jul;59(1):262-4.  
 
de Valk-de Roo GW, Stehouwer CD, Lambert J, Schalkwijk CG, van der Mooren MJ, Kluft 
C, Netelenbos C. Plasma homocysteine is weakly correlated with plasma endothelin and von 
Willebrand factor but not with endothelium-dependent vasodilatation in healthy 
postmenopausal women. Clin Chem. 1999 Aug;45(8 Pt 1):1200-5.  
 
Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, 
Goodfellow J. Folate improves endothelial function in coronary artery disease: an effect 
mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 2001 
Jul;21(7):1196-202.  
 
Dreon DM, Fernstrom HA, Miller B, Krauss RM. Apolipoprotein E isoform phenotype and 
LDL subclass response to a reduced-fat diet. Arterioscler Thromb Vasc Biol. 1995 
Jan;15(1):105-11.  
 
Dreon DM, Krauss RM. Diet-gene interactions in human lipoprotein metabolism.J Am Coll 
Nutr. 1997 Aug;16(4):313-24.  
 
Edwards DG, Schofield RS, Lennon SL, Pierce GL, Nichols WW, Braith RW. Effect of 
exercise training on endothelial function in men with coronary artery disease. Am J Cardiol. 
2004 Mar 1;93(5):617-20.  
 
Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998 Jan 
3;316(7124):61-6.  
 
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a 
simple, graphical test. BMJ. 1997a Sep 13;315(7109):629-34. 
 
Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997b 
Dec 6;315(7121):1533-7. 
 
Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-
wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8.  
 
Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, Stuehlinger M, Lin 
KY, Cooke JP, Morrow JD, Ridker PM, Rifai N, Miller E, Witztum JL, Mietus-Snyder M. 
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: 
Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003 Sep 
2;108(9):1059-63. Epub 2003 Aug 11.  
 88
 
Fathi R, Haluska B, Isbel N, Short L, Marwick TH. The relative importance of vascular 
structure and function in predicting cardiovascular events. J Am Coll Cardiol. 2004 Feb 
18;43(4):616-23.  
 
Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader 
DJ, Edman JS, Klein S. A randomized trial of a low-carbohydrate diet for obesity. N Engl J 
Med. 2003 May 22;348(21):2082-90.  
 
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer 
M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular 
disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 
May;10(1):111-3.  
 
Fuchsjäger-Mayrl G, Pleiner J, Wiesinger GF, Sieder AE, Quittan M, Nuhr MJ, Francesconi 
C, Seit HP, Francesconi M, Schmetterer L, Wolzt M. Exercise training improves vascular 
endothelial function in patients with type 1 diabetes.Diabetes Care. 2002 Oct;25(10):1795-
801.  
 
Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory 
enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987 May 
28;316(22):1371-5.  
 
Gnasso A, Irace C, Carallo C, De Franceschi MS, Motti C, Mattioli PL, Pujia A. In vivo 
association between low wall shear stress and plaque in subjects with asymmetrical carotid 
atherosclerosis. Stroke. 1997 May;28(5):993-8.  
 
Gokce N, Holbrook M, Hunter LM, Palmisano J, Vigalok E, Keaney JF Jr, Vita JA. Acute 
effects of vasoactive drug treatment on brachial artery reactivity. J Am Coll Cardiol. 2002b 
Aug 21;40(4):761-5.  
 
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification 
for postoperative cardiovascular events via noninvasive assessment of endothelial function: a 
prospective study. Circulation. 2002a Apr 2;105(13):1567-72. 
 
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. 
Predictive value of noninvasively determined endothelial dysfunction for long-term 
cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003 
May 21;41(10):1769-75.  
 
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as 
a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 
May;62(5):707-14.  
Green DJ, Maiorana A, O'Driscoll G, Taylor R. Effect of exercise training on endothelium-
derived nitric oxide function in humans. J Physiol. 2004 Nov 15;561(Pt 1):1-25. Epub 2004 
Sep 16.  
 
 89
Guangda X, Yuhua W. Apolipoprotein e4 allele and endothelium-dependent arterial dilation 
in Type 2 diabetes mellitus without angiopathy. Diabetologia. 2003 Apr;46(4):514-9. Epub 
2003 Mar 25. 
 
Guangda X, Linshuang Z, Jie H, Ling Y, Huijuan X. Apo e4 allele is associated with 
endothelium-dependent arterial dilation in women with type 2 diabetes. Diabetes Res Clin 
Pract. 2006 May;72(2):155-61. Epub 2005 Dec 6.  
 
Guazzi M, Reina G, Tumminello G, Guazzi MD. Improvement of alveolar-capillary 
membrane diffusing capacity with exercise training in chronic heart failure. J Appl Physiol. 
2004 Nov;97(5):1866-73. Epub 2004 Jun 25.  
 
Hagberg JM, Wilund KR, Ferrell RE.APO E gene and gene-environment effects on plasma 
lipoprotein-lipid levels. Physiol Genomics. 2000 Dec 18;4(2):101-108. 
 
Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A, 
Caballero AE, Economides PA, Veves A, Horton ES. Lifestyle modification improves 
endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care. 
2003 Jul;26(7):2119-25.  
 
Hanratty CG, McAuley DF, McGrath LT, Young IS, Johnston GD. Hyperhomocysteinaemia 
in young adults is not associated with impaired endothelial function. Clin Sci (Lond). 2001 
Jan;100(1):67-72.  
 
Heber D, Ashley JM, McCarthy WJ, Solares ME, Leaf DA, Chang LJ, Elashoff RM. 
Assessment of adherence to a low-fat diet for breast cancer prevention. Prev Med. 1992 
Mar;21(2):218-27.  
 
Hedges, LV and Okin I:  Statistical methods for meta-analysis.  New York: Academic Press, 
1985. 
 
Henderson MM, Kushi LH, Thompson DJ, Gorbach SL, Clifford CK, Insull W Jr, 
Moskowitz M, Thompson RS. Feasibility of a randomized trial of a low-fat diet for the 
prevention of breast cancer: dietary compliance in the Women's Health Trial Vanguard 
Study. Prev Med. 1990 Mar;19(2):115-33.  
 
Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic 
activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll 
Cardiol. 2002 Feb 20;39(4):683-8.  
 
Hixson JE, Powers PK. Restriction isotyping of human apolipoprotein A-IV: rapid typing of 
known isoforms and detection of a new isoform that deletes a conserved repeat. J Lipid Res. 
1991 Sep;32(9):1529-35.  
 
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene 
amplification and cleavage with HhaI. J Lipid Res. 1990 Mar;31(3):545-8.  
 
 90
Holubkov R, Karas RH, Pepine CJ, Rickens CR, Reichek N, Rogers WJ, Sharaf BL, Sopko 
G, Merz CN, Kelsey SF, McGorray SP, Reis SE. Large brachial artery diameter is associated 
with angiographic coronary artery disease in women. Am Heart J. 2002 May;143(5):802-7.  
 
Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep. 
2005 Feb 28;53(15):1-48.  
 
Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. Interaction of 5-
methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart 
Circ Physiol. 2002 Jun;282(6):H2167-72.  
 
Irace C, Carallo C, Crescenzo A, Motti C, De Franceschi MS, Mattioli PL, Gnasso A. 
NIDDM is associated with lower wall shear stress of the common carotid artery. Diabetes. 
1999 Jan;48(1):193-7.  
 
Irace C, Ceravolo R, Notarangelo L, Crescenzo A, Ventura G, Tamburrini O, Perticone F, 
Gnasso A. Comparison of endothelial function evaluated by strain gauge plethysmography 
and brachial artery ultrasound. Atherosclerosis. 2001 Sep;158(1):53-9.  
 
Jacobs DR Jr, Anderson JT, Hannan P, Keys A, Blackburn H. Variability in individual serum 
cholesterol response to change in diet. Arteriosclerosis. 1983 Jul-Aug;3(4):349-56.  
 
Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid 
fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999 
May 13;340(19):1449-54.  
 
Jansen S, Lopez-Miranda J, Ordovas JM, Zambrana JL, Marin C, Ostos MA, Castro P, 
McPherson R, Lopez Segura F, Blanco A, Jimenez Pereperez JA, Perez-Jimenez F. Effect of 
360His mutation in apolipoprotein A-IV on plasma HDL-cholesterol response to dietary fat. 
J Lipid Res. 1997 Oct;38(10):1995-2002. 
 
Jansen S, Lopez-Miranda J, Salas J, Ordovas JM, Castro P, Marin C, Ostos MA, Lopez-
Segura F, Jimenez-Pereperez JA, Blanco A, Perez-Jimenez F. Effect of 347-serine mutation 
in apoprotein A-IV on plasma LDL cholesterol response to dietary fat. Arterioscler Thromb 
Vasc Biol. 1997 Aug;17(8):1532-8. 
 
Jasperse JL, Laughlin MH. Endothelial function and exercise training: evidence from studies 
using animal models. Med Sci Sports Exerc. 2006 Mar;38(3):445-54.  
 
Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric 
oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in 
vivo. Circulation. 1995 Mar 1;91(5):1314-9.  
 
Jodoin I, Bussières LM, Tardif JC, Juneau M. Effect of a short-term primary prevention 
program on endothelium-dependent vasodilation in adults at risk for atherosclerosis. Can J 
Cardiol. 1999 Jan;15(1):83-8.  
 
 91
John SW, Weitzner G, Rozen R, Scriver CR. A rapid procedure for extracting genomic DNA 
from leukocytes. Nucleic Acids Res. 1991 Jan 25;19(2):408. 
 
Kaku B, Mizuno S, Ohsato K, Murakami T, Moriuchi I, Arai Y, Nio Y, Hirase H, Nagata M, 
Takahashi Y, Ohnaka M. The correlation between coronary stenosis index and flow-
mediated dilation of the brachial artery. Jpn Circ J. 1998 Jun;62(6):425-30.  
 
Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A 
possible risk factor for coronary artery disease. J Clin Invest. 1986 May;77(5):1482-6.  
 
Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile 
methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am 
J Hum Genet. 1991 Mar;48(3):536-45.  
 
Katan MB, Beynen AC. Characteristics of human hypo- and hyperresponders to dietary 
cholesterol. Am J Epidemiol. 1987 Mar;125(3):387-99. 
 
Katan MB, Beynen AC, de Vries JH, Nobels A. Existence of consistent hypo- and 
hyperresponders to dietary cholesterol in man. Am J Epidemiol. 1986 Feb;123(2):221-34.  
 
Kaufman S. Some metabolic relationships between biopterin and folate: implications for the 
"methyl trap hypothesis." Neurochem Res. 1991 Sep;16(9):1031-6.  
 
Kelly AS, Wetzsteon RJ, Kaiser DR, Steinberger J, Bank AJ, Dengel DR. Inflammation, 
insulin, and endothelial function in overweight children and adolescents: the role of exercise. 
J Pediatr. 2004 Dec;145(6):731-6.  
 
Kesäniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in 
man is related to apoprotein E phenotype.J Clin Invest. 1987 Aug;80(2):578-81. 
 
Khoury MJ, Davis R, Gwinn M, Lindegren ML, Yoon P. Do we need genomic research for 
the prevention of common diseases with environmental causes? Am J Epidemiol. 2005 May 
1;161(9):799-805.  
 
Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by 
levels and ratios. Ann Intern Med. 1994 Nov 1;121(9):641-7.  
 
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies 
Collaboration Group. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a 
meta-analysis. JAMA. 2002 Oct 23-30;288(16):2023-31.  
 
Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den 
Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild 
hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene 
is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996 Jan;58(1):35-41.  
 
 92
Kobayashi N, Tsuruya Y, Iwasawa T, Ikeda N, Hashimoto S, Yasu T, Ueba H, Kubo N, Fujii 
M, Kawakami M, Saito M. Exercise training in patients with chronic heart failure improves 
endothelial function predominantly in the trained extremities. Circ J. 2003 Jun;67(6):505-10.  
 
Lambert J, van den Berg M, Steyn M, Rauwerda JA, Donker AJ, Stehouwer CD. Familial 
hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility 
of large arteries. Cardiovasc Res. 1999 Jun;42(3):743-51.  
 
Laughlin MH. Endothelium-mediated control of coronary vascular tone after chronic 
exercise training. Med Sci Sports Exerc. 1995 Aug;27(8):1135-44. 
 
Laughlin MH, Rubin LJ, Rush JW, Price EM, Schrage WG, Woodman CR. Short-term 
training enhances endothelium-dependent dilation of coronary arteries, not arterioles. J Appl 
Physiol. 2003 Jan;94(1):234-44. Epub 2002 Sep 13.  
 
Laughlin MH, Welshons WV, Sturek M, Rush JW, Turk JR, Taylor JA, Judy BM, 
Henderson KK, Ganjam VK. Gender, exercise training, and eNOS expression in porcine 
skeletal muscle arteries. J Appl Physiol. 2003 Jul;95(1):250-64. Epub 2003 Mar 7.  
 
Laurent S, Lacolley P, Brunel P, Laloux B, Pannier B, Safar M. Flow-dependent vasodilation 
of brachial artery in essential hypertension. Am J Physiol. 1990 Apr;258(4 Pt 2):H1004-11.  
 
Lavrencic A, Salobir BG, Keber I. Physical training improves flow-mediated dilation in 
patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol. 2000 
Feb;20(2):551-5.  
 
Lee-Han H, Cousins M, Beaton M, McGuire V, Kriukov V, Chipman M, Boyd N. 
Compliance in a randomized clinical trial of dietary fat reduction in patients with breast 
dysplasia. Am J Clin Nutr. 1988 Sep;48(3):575-86.  
 
Lind L, Johansson K, Hall J. The effects of mental stress and the cold pressure test on flow-
mediated vasodilation. Blood Press. 2002;11(1):22-7.  
 
Maiorana A, O'Driscoll G, Dembo L, Goodman C, Taylor R, Green D. Exercise training, 
vascular function, and functional capacity in middle-aged subjects. Med Sci Sports Exerc. 
2001 Dec;33(12):2022-8.  
 
Masson LF, McNeill G, Avenell A. Genetic variation and the lipid response to dietary 
intervention: a systematic review. Am J Clin Nutr. 2003 May;77(5):1098-111. 
 
Mayer B, Werner ER. In search of a function for tetrahydrobiopterin in the biosynthesis of 
nitric oxide. Naunyn Schmiedebergs Arch Pharmacol. 1995 May;351(5):453-63.  
 
McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: 
a randomised, controlled trial. BMC Med Res Methodol. 2007 Jul 3;7:30. 
 
 93
McNamara DJ, Kolb R, Parker TS, Batwin H, Samuel P, Brown CD, Ahrens EH Jr. 
Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality 
and cholesterol quantity. J Clin Invest. 1987 Jun;79(6):1729-39.  
 
Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial 
dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002 Aug 
7;40(3):505-10.  
 
Moriguchi J, Itoh H, Harada S, Takeda K, Hatta T, Nakata T, Sasaki S. Low frequency 
regular exercise improves flow-mediated dilatation of subjects with mild hypertension. 
Hypertens Res. 2005 Apr;28(4):315-21.  
 
Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated 
measures and independent-groups designs. Psychol Methods. 2002 Mar;7(1):105-25.  
 
Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: 
from the Framingham Study. Am J Cardiol. 2006 Feb 1;97(3):372-5. 
 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive 
Summary of The Third Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. 
 
Neunteufl T, Heher S, Katzenschlager R, Wölfl G, Kostner K, Maurer G, Weidinger F. Late 
prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. 
Am J Cardiol. 2000 Jul 15;86(2):207-10.  
 
Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, 
Weidinger F. Systemic endothelial dysfunction is related to the extent and severity of 
coronary artery disease. Atherosclerosis. 1997 Feb 28;129(1):111-8.  
 
Ng CK, Chan AP, Cheng A. Impairment of endothelial function--a possible mechanism for 
atherosclerosis of a high-fat meal intake. Ann Acad Med Singapore. 2001 Sep;30(5):499-
502. Erratum in: Ann Acad Med Singapore 2001 Nov;30(6):679.  
 
Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, 
Desai MY, Hazen SL, Kapadia SR, Nissen SE Statins, high-density lipoprotein cholesterol, 
and regression of coronary atherosclerosis. JAMA. 2007 Feb 7;297(5):499-508.  
 
Nicolosi RJ, Wilson TA, Lawton C, Handelman GJ. Dietary effects on cardiovascular disease 
risk factors: beyond saturated fatty acids and cholesterol. J Am Coll Nutr. 2001 Oct;20(5 
Suppl):421S-427S; discussion 440S-442S. 
 
Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC. 
Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a 
meta-analysis of randomized controlled trials. Arch Intern Med. 2006 Feb 13;166(3):285-93. 
 
 94
Ordovas JM, Galluzzi JR. Genetic predictors of plasma lipid response to diet intervention. 
Curr Atheroscler Rep. 1999 Nov;1(3):196-203. 
 
Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. 
Gene-diet interaction in determining plasma lipid response to dietary intervention. 
Atherosclerosis. 1995 Dec;118 Suppl:S11-27. 
 
Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan 
SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart 
disease? The Lifestyle Heart Trial. Lancet. 1990 Jul 21;336(8708):129-33.  
 
Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, 
Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes 
for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: 
JAMA 1999 Apr 21;281(15):1380.  
 
Parish TR, Allen JD, Tulley R, Wilson JB, Smith S, Lefevre M, Welsch MA. Association of 
brachial artery size with cardiovascular risk factors. Med. Sci. Sports Exerc. 2003 May;35 (5) 
Suppl: S41. 
 
Patti G, Pasceri V, Melfi R, Goffredo C, Chello M, D'Ambrosio A, Montesanti R, Di 
Sciascio G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing 
coronary stent implantation. Circulation. 2005 Jan 4;111(1):70-5.  
 
Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello 
M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial 
dysfunction in hypertensive patients. Circulation. 2001 Jul 10;104(2):191-6.  
 
Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, Salvetti A. 
Supplementation with vitamins C and E improves arterial stiffness and endothelial function 
in essential hypertensive patients. Am J Hypertens. 2007 Apr;20(4):392-7. 
 
Prior BM, Lloyd PG, Yang HT, Terjung RL. Exercise-induced vascular remodeling. Exerc 
Sport Sci Rev. 2003 Jan;31(1):26-33. 
 
Pullin CH, Wilson JF, Ashfield-Watt PA, Clark ZE, Whiting JM, Lewis MJ, McDowell IF. 
Influence of methylenetetrahydrofolate reductase genotype, exercise and other risk factors on 
endothelial function in healthy individuals. Clin Sci (Lond). 2002 Jan;102(1):45-50. 
 
Rader JI. Folic acid fortification, folate status and plasma homocysteine. J Nutr. 2002 
Aug;132(8 Suppl):2466S-2470S.  
 
Raitakari M, Ilvonen T, Ahotupa M, Lehtimäki T, Harmoinen A, Suominen P, Elo J, Hartiala 
J, Raitakari OT. Weight reduction with very-low-caloric diet and endothelial function in 
overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol. 2004 
Jan;24(1):124-8. Epub 2003 Dec 1.  
 
 95
Raitakari OT, Rönnemaa T, Järvisalo MJ, Kaitosaari T, Volanen I, Kallio K, Lagström H, 
Jokinen E, Niinikoski H, Viikari JS, Simell O. Endothelial function in healthy 11-year-old 
children after dietary intervention with onset in infancy: the Special Turku Coronary Risk 
Factor Intervention Project for children (STRIP). Circulation. 2005 Dec 13;112(24):3786-94. 
Epub 2005 Dec 5.  
 
Rakobowchuk M, McGowan CL, de Groot PC, Hartman JW, Phillips SM, MacDonald MJ. 
Endothelial function of young healthy males following whole body resistance training. J 
Appl Physiol. 2005 Jun;98(6):2185-90. Epub 2005 Jan 27.  
 
Ravikumar R, Deepa R, Shanthirani C, Mohan V. Comparison of carotid intima-media 
thickness, arterial stiffness, and brachial artery flow mediated dilatation in diabetic and 
nondiabetic subjects (The Chennai Urban Population Study [CUPS-9]). Am J Cardiol. 2002 
Oct 1;90(7):702-7.  
 
Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. 
Annu Rev Med. 1998;49:31-62.  
 
Regensteiner JG, Popylisen S, Bauer TA, Lindenfeld J, Gill E, Smith S, Oliver-Pickett CK, 
Reusch JE, Weil JV. Oral L-arginine and vitamins E and C improve endothelial function in 
women with type 2 diabetes. Vasc Med. 2003;8(3):169-75.  
 
Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a 
comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard 
cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 
16;285(19):2481-5.  
 
Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, 
Savon SR, Selhub J, Nissen SE, et al. Hyperhomocysteinemia and low pyridoxal phosphate. 
Common and independent reversible risk factors for coronary artery disease. Circulation. 
1995 Nov 15;92(10):2825-30.  
 
Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 
20;314(8):488-500. 
 
Saito M, Eto M, Nitta H, Kanda Y, Shigeto M, Nakayama K, Tawaramoto K, Kawasaki F, 
Kamei S, Kohara K, Matsuda M, Matsuki M, Kaku K. Effect of apolipoprotein E4 allele on 
plasma LDL cholesterol response to diet therapy in type 2 diabetic patients.Diabetes Care. 
2004 Jun;27(6):1276-80. 
 
Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams 
M, Gracely EJ, Stern L. A low-carbohydrate as compared with a low-fat diet in severe 
obesity. N Engl J Med. 2003 May 22;348(21):2074-81. 
 
Schaefer EJ, Lamon-Fava S, Ausman LM, Ordovas JM, Clevidence BA, Judd JT, Goldin 
BR, Woods M, Gorbach S, Lichtenstein AH. Individual variability in lipoprotein cholesterol 




Shechter M, Beigel R, Freimark D, Matetzky S, Feinberg MS. Short-term sibutramine 
therapy is associated with weight loss and improved endothelial function in obese patients 
with coronary artery disease.Am J Cardiol. 2006 Jun 1;97(11):1650-3. Epub 2006 Apr 7.  
 
Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, 
Deanfield JE. Non-invasive measurement of human endothelium dependent arterial 
responses: accuracy and reproducibility. Br Heart J. 1995 Sep;74(3):247-53. 
 
Spieker LE, Hürlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, Hayoz D, Deanfield 
JE, Lüscher TF, Noll G. Mental stress induces prolonged endothelial dysfunction via 
endothelin-A receptors. Circulation. 2002 Jun 18;105(24):2817-20.  
 
Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, 
Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial 
infarction in US physicians. JAMA. 1992 Aug 19;268(7):877-81.  
 
Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of 
cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991 Aug 
8;325(6):373-81.  
 
Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams M, Gracely EJ, 
Samaha FF. The effects of low-carbohydrate versus conventional weight loss diets in 
severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004 May 
18;140(10):778-85. 
 
Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ. Folic acid 
reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000 Jun 9;86(11):1129-
34.  
 
Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, 
Kurita A. Endothelium-dependent flow-mediated vasodilation in coronary and brachial 
arteries in suspected coronary artery disease. Am J Cardiol. 1998 Dec 15;82(12):1535-9, A7-
8.  
 
Takase B, Etsuda H, Matsushima Y, Ayaori M, Kusano H, Hamabe A, Uehata A, Ohsuzu F, 
Ishihara M, Kurita A. Effect of chronic oral supplementation with vitamins on the endothelial 
function in chronic smokers. Angiology. 2004 Nov-Dec;55(6):653-60.  
 
Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is 
associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997 
Mar 4;95(5):1119-21.  
 
Thuesen L, Henriksen LB, Engby B. One-year experience with a low-fat, low-cholesterol 
diet in patients with coronary heart disease. Am J Clin Nutr. 1986 Aug;44(2):212-9.  
 




Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive 
high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular 
microparticles in healthy men. J Thromb Haemost. 2006 May;4(5):1003-10. 
 
U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary 
Guidelines for Americans, 2005. Sixth edition, Washington, DC: US Government Printing 
Office, January 2005. 
 
Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction 
by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Lond). 1999 
Mar;96(3):235-9.  
 
Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. 
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric 
oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998 Mar 3;97(8):752-6.  
 
Vona M, Rossi A, Capodaglio P, Rizzo S, Servi P, De Marchi M, Cobelli F. Impact of 
physical training and detraining on endothelium-dependent vasodilation in patients with 
recent acute myocardial infarction. Am Heart J. 2004 Jun;147(6):1039-46.  
 
Walden CE, McCann BS, Retzlaff B, Dowdy A, Hanson M, Fish B, Fitzpatrick V, Follette 
W, Parker D, Gey G, et al. Alternative fat-restricted diets for hypercholesterolemia and 
combined hyperlipidemia: feasibility, design, subject recruitment, and baseline 
characteristics of the dietary alternatives study. J Am Coll Nutr. 1991 Oct;10(5):429-42.  
 
Walsh JH, Bilsborough W, Maiorana A, Best M, O'Driscoll GJ, Taylor RR, Green DJ. 
Exercise training improves conduit vessel function in patients with coronary artery disease. J 
Appl Physiol. 2003a Jul;95(1):20-5.  
 
Walsh JH, Yong G, Cheetham C, Watts GF, O'Driscoll GJ, Taylor RR, Green DJ. Effects of 
exercise training on conduit and resistance vessel function in treated and untreated 
hypercholesterolaemic subjects. Eur Heart J. 2003b Sep;24(18):1681-9.  
 
Wang J, Wolin MS, Hintze TH. Chronic exercise enhances endothelium-mediated dilation of 
epicardial coronary artery in conscious dogs. Circ Res. 1993 Nov;73(5):829-38.  
 
Watts K, Beye P, Siafarikas A, Davis EA, Jones TW, O'Driscoll G, Green DJ. Exercise 
training normalizes vascular dysfunction and improves central adiposity in obese 
adolescents. J Am Coll Cardiol. 2004a May 19;43(10):1823-7.  
 
Watts K, Beye P, Siafarikas A, O'Driscoll G, Jones TW, Davis EA, Green DJ. Effects of 
exercise training on vascular function in obese children. J Pediatr. 2004 May;144(5):620-5.  
 
Welsch MA, Allen JD, Geaghan JP. Stability and reproducibility of brachial artery flow-
mediated dilation. Med Sci Sports Exerc. 2002 Jun;34(6):960-5.  
 
 98
Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial 
dysfunction. J Am Coll Cardiol. 2003 Oct 1;42(7):1149-60.  
 
Williams MJ, Sutherland WH, McCormick MP, de Jong SA, Walker RJ, Wilkins GT. 
Impaired endothelial function following a meal rich in used cooking fat. J Am Coll Cardiol. 
1999 Mar 15;33(4):1050-5.  
 
Wilson JB, Allen J, Thomson J, Tulley R, Welsch M: Exercise Training and Flow Mediated 
Dilation: A Meta-Analysis. Med Sci Sports Exerc. 2007 39(5) Suppl. 
 
Wilson JB, Welsch M, Allen J, Thomson J, Tulley R, Lefevre M. The association of 
homocysteine and related factors to brachial artery diameter and flow-mediated dilation. 
Metabolism. 2007 May;56(5):641-8.  
 
Wiltshire EJ, Gent R, Hirte C, Pena A, Thomas DW, Couper JJ. Endothelial dysfunction 
relates to folate status in children and adolescents with type 1 diabetes. Diabetes. 2002 
Jul;51(7):2282-6.  
 
Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, 
Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction 
in humans. Circulation. 1997 Oct 21;96(8):2542-4.  
 
Woodman CR, Muller JM, Rush JW, Laughlin MH, Price EM. Flow regulation of ecNOS 
and Cu/Zn SOD mRNA expression in porcine coronary arterioles. Am J Physiol. 1999 
Mar;276(3 Pt 2):H1058-63.  
 
Xu CF, Tikkanen MJ, Huttunen JK, Pietinen P, Bütler R, Humphries S, Talmud P. 
Apolipoprotein B signal peptide insertion/deletion polymorphism is associated with Ag 
epitopes and involved in the determination of serum triglyceride levels. J Lipid Res. 1990 
Jul;31(7):1255-61.  
 
Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, 
ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, 
controlled trial. Ann Intern Med. 2004 May 18;140(10):769-77. 
 
Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in 










Joanie Brocato Wilson was born in March 1969 in Baton Rouge, Louisiana.  She is the 
daughter of John and Brenda Brocato, wife of J. Scott Wilson, and mother of Connor (10) and 
Parker Wilson (7).  She earned her Bachelor of Science in Medical Technology from Louisiana 
State University Medical Center in New Orleans, Louisiana, in 1992.  Upon graduation and 
successful completion of her American Society of Clinical Pathology registry, she worked at Earl 
K. Long Hospital as a Medical Technologist in Clinical Chemistry for one year.  She joined 
Pennington Biomedical Research Center in 1992 where she was a Research Associate/Manager 
of Personnel, Business and Continuing Education.  In 1993, she became licensed by the 
Louisiana State Board of Medical Examiners as a Clinical Laboratory Scientist. During this time 
she began graduate school. In 1997 her son, Connor Scott Wilson, was born and in 2000 her 
daughter, Parker Alaine Wilson was born.  After almost ten years at Pennington Biomedical 
Research Center, in 2002, she became a DNA Analyst at the Louisiana State Police Crime 
Laboratory.  In June 2007, she became the DNA Unit Supervisor.  She has been court qualified 
as a DNA expert over twelve times and has worked on cases such as the Louisiana Serial Killers, 
Louisiana State University 2007 Homicides, and hundreds of other murders and sexual assaults.  
She joined Louisiana State University in the Department of Kinesiology in 2003 and is currently 
a doctoral candidate.  She plans to continue to merge her interests in molecular biology, 
biochemistry, and functionality. 
